CONFERENCE PROGRAM

National Society of Genetic Counselors

Conference Program Sponsored by:

BAYLOR GENETICS

Booth #525

NOVEMBER 14-17, 2018 ▪ ATLANTA, GA

MYRIAD IS COMMITTED TO YOUR PATIENTS

Patient safety

Peer reviewed validation, with >99.98% accuracy[1]

Powerful and unique classification tools with a lifetime commitment to reclassification

Definitive results for over 42% of VUS classifications from other labs[2]

Strong reclassification program - over the 10 years between 2006 and 2016, 2,868 variants were reclassified, providing clarity to 52,297 patients.

Patient affordability

3 out of 4 patients pay $0 for testing

The average out of pocket cost for patients is $54

In network with the vast majority of insurance plans

Myriad Financial Assistance Program for both uninsured and underinsured patients

Patient accessibility

Once test is completed, Myriad will not withhold results while waiting for payment

Medical support and clinical solutions from patient identification to result delivery

Patient friendly clinical results and myRisk Management Tool that empowers patient education

Multiple test options available with results in 14 days or less

1. Judkins T, et al, Development and analytical validation of a 25-gene next generation sequencing panel that includes BRCA1 and BRCA2 genes to assess hereditary cancer risk; BMC Cancer, 2014.

2. Gradishar W, et al. Clinical variant classification: a comparison of public databases and a commercial testing laboratory; The Oncologist, 2017.

Please stop by our booth #1025 to learn more about what we offer for you and your patients!

myriad® WHEN DECISIONS MATTER | MYRIAD myRisk® Hereditary Cancer

www.MyriadmyRisk.com

Myriad, the Myriad logo, Myriad myRisk and the Myriad myRisk logo are either trademarks or registered trademarks of Myriad Genetics, Inc. in the United States and other jurisdictions. ©2018

Welcome to Atlanta!

On behalf of the National Society of Genetic Counselors (NSGC), the Annual Conference Program Committee and the NSGC Board of Directors, thank you for joining us!

NSGC is excited to bring you education and networking opportunities designed to help you adapt, evolve and thrive in the field of genetic counseling. Educational sessions will cover a variety of topics at the forefront of genomics, such as hereditary hematologic malignancies, testing methods, bioinformatics and disorders of sex development.

Educational highlights you do not want to miss include: *Conflicts of Interest: We Are Stuck With It, So How Should We Address It?*, *NHGRI: Establishing a 2020 Vision for Genetics*, the *Jane Engelberg Memorial Fellowship (JEMF) Presentation* and the *Professional Issues Panel*. You can make the most of your Annual Conference experience by building your schedule around education sessions specific to your professional interests.

The NSGC Annual Conference is about more than just education! We encourage you to take advantage of the Welcome Reception, SIG meetings, Program Reunions and the NSGC Central area to network with more than 2,200 of your peers. Discover the latest product offerings and services for our profession in the Exhibitor Suite. Catch up with old friends and make new, lasting connections during this year's conference.

We hope you enjoy your time in Atlanta, learning about the latest innovations and developments in the profession of genetic counseling and exploring this energetic city!

COLLEEN SCHMITT, MS, CGC

2018 Program Committee Chair

KAT LAFFERTY, MS, CGC

2018 Program Committee Vice-Chair

Table of Contents

Conference Information	5
Schedule-at-a-Glance	8
Convention Center Maps	12
Reunion Information	14
Session Objectives	15
Platform Presentations	26
Posters with Authors	29
Vendor-Sponsored Presentations	48
NSGC Sponsors	49
NSGC Awards	51
Annual Conference Program Committee	52
Networking Activities & Meetings	53
Meals and Refreshments	54
Exhibitor Directory	56
Exhibitor Suite Map	57
Exhibitor Index	58

Download the Official Annual Conference Mobile App

NSGC delivers everything Annual Conference directly to your fingertips via the 2018 NSGC Annual Conference mobile app. View conference session descriptions, speakers and schedule information. Use the interactive maps to navigate the Exhibitor Suite with ease, search the exhibitor directory and stay in-the-know with conference alerts.

On your smartphone or tablet, search for "NSGC" in your app store. Follow what others are saying or post your own insights on Twitter during the Annual Conference using **#NSGC18**.

beBRCAware

@beBRCAware @beBRCAware @beBRCAware

Are you BRCAware?

Being BRCAware means understanding the importance of testing for a *BRCA* mutation (*BRCA*m). Because *BRCA*m testing can inform patients of their potential cancer risk and treatment options, early testing for a *BRCA*m is **critical.**[1]

Visit **Booth #610** to learn more about *BRCA*m testing.

Wednesday, November 14, 6:30-7:30 PM

You're invited!
Stop by our sponsored presentation to get the latest information on *BRCA*m testing.

Reference: 1. BRCA1 and BRCA2: cancer risk and genetic testing. National Cancer Institute website. https://www.cancer.gov/about-cancer/causes-prevention/genetics/brca-fact-sheet#q1. Accessed August 1, 2018.

©2018 AstraZeneca. All rights reserved. US-22408 8/18

AstraZeneca

Conference Information

Statement of Purpose

The NSGC Annual Conference showcases advancements across the breadth of the genetic counseling profession to provide education and build community. Attendees will gain knowledge of clinical and scientific best practices and insights into emerging research. The conference provides a unique opportunity to engage and network with colleagues and pursue professional development.

Evaluation Process/Claiming CEUs

Individuals claiming CEUs must complete evaluations, however NSGC greatly appreciates feedback from all attendees. An attendance verification code will be provided in each session. Each session listing (beginning on page 15) has a blank space to assist you in tracking verification codes for the sessions that you have attended. Signs with session codes are posted inside of each session room. Some attendees also find it helpful to take a photo of the sign as a reminder of sessions attended and codes. To complete your evaluations, follow these steps:

1. Log in to the NSGC website, and go to **www.nsgc.org/conferenceevaluations**

2. Click on the "Evaluation" link to be directed to the evaluation website.

3. For each session, add the attendance verification code that you received in the session room and then evaluate the session.

4a. Save each session as you go. The website will log you out after 10 minutes of inactivity. (If this happens, you must go back to the NSGC website and repeat steps 1 and 2 to log in again.)

4b. PLEASE NOTE: Although your responses to the individual session evaluation questions will save each time you click "Save and Continue," the attendance verification code will need to be re-entered if you re-enter that session to edit your responses.

5. Once you have completed evaluations for all sessions attended, you will be able to evaluate the overall conference by selecting "Return to Registered Events."

6. Review your evaluation to make sure you claimed credit for each session you attended. Then print your final certificate of credits earned for your records. Attendees are responsible for maintaining their own record of credits earned.

Note: Once you have printed your certificate you are not able to go back and edit any more sessions.

The deadline to complete evaluations is December 19, 2018. Please contact the NSGC Executive Office at **nsgc@nsgc.org** if you need assistance.

NSGC will not issue CEU certificates if an evaluation is not completed by December 19, 2018. No exceptions will be made.

Overall Conference Evaluation

To evaluate the overall conference, please follow the steps listed below:

1. Log in to the NSGC website, and go to **www.nsgc.org/conferenceevaluations**.

2. Click on the "Evaluation" link to enter the evaluation website.

3. Select the "Overall/Post-event" link to evaluate the conference.

2018 Annual Conference Session Recordings

View sessions you miss in Atlanta, earn additional CEUs and review the valuable information you gathered during the conference by pre-purchasing the 2018 Annual Conference recordings. The conference recordings package includes synced audio and PowerPoint Presentations for all pre-conference symposia, plenary and educational breakout sessions.*

The full session recordings package is available for a reduced price of $149 for all conference attendees.** Registered attendees will be able to order the Annual Conference recordings through November 18, 2018, at the discounted rate, or following the conference at an increased rate. The Annual Conference recordings package will be made available to purchasers in January 2019.

To earn Category 1 CEUs for recordings, it is required that you complete and pass a quiz included at the conclusion of each session.

Visit **www.nsgc.org/conference** or stop by the registration desk to add session recordings to your registration.

** With speaker approval*

***Discounted package rates only available when purchased with conference registration.*

Attendee List Information

Attendee lists, along with session handouts, are posted on the NSGC website. An updated list will be posted following the conference. Attendee lists are provided solely for networking and may not be used for solicitation purposes. NSGC is not responsible for errors or omissions.

Handouts and Presentations

NSGC offers electronic versions of session handouts when submitted in advance by speakers. All session handouts (provided by speakers) are posted on the NSGC website and in the NSGC Annual Conference mobile app, and will be available until March 1, 2019.

To download session handouts go to:
www.nsgc.org/conferencehandouts

To download pre-conference symposia handouts go to:
www.nsgc.org/PCShandouts

Conference Information continued

Registration Hours

HALL C1 FOYER

Tuesday, November 13
5:00 pm – 7:30 pm

Wednesday, November 14
7:00 am – 8:00 pm

Thursday, November 15
6:30 am – 7:00 pm

Friday, November 16
7:00 am – 7:00 pm

Saturday, November 17
7:30 am – 12:00 pm

Exhibitor Suite Hours

EXHIBIT HALL C1/C2

Wednesday, November 14
5:30 pm – 8:30 pm

Thursday, November 15
10:05 am – 10:45 am
11:45 am – 1:30 pm
3:45 pm – 4:15 pm
5:30 pm – 8:00 pm

Friday, November 16
10:05 am – 10:45 am
12:00 pm – 3:00 pm

Job Boards

Bulletin boards with push-pins are available in the booth across from the NSGC Central area in the Exhibitor Suite for attendees to post job opportunities. Other forms of advertising are not permitted. Posted material will be monitored and inappropriate information is subject to removal at NSGC's discretion.

Sponsored by: NORTHSIDE HOSPITAL CANCER INSTITUTE "BUILT TO BEAT CANCER"

Business Center Hours

There are two Business Centers located in the Georgia World Congress Center:

The Business Center in Building B, located in the main lobby, is open from 8:30 am – 5:00 pm M-F.

The Business Center in Building C is open from 8:30 am – 5:00 pm on November 14-16.

Internet Access

Wireless Internet is available in all meeting spaces and common areas at the Atlanta Convention Center. Internet at the Convention Center can be accessed by using the network **#wearemyriad**. The password is **nsgc2018**.

To get onto the WiFi:

1. Connect to the Myriad network

2. Enter password "nsgc2018"

3. Launch a web browser and click on the connect button on the splash page

NSGC gratefully acknowledges our Wireless Internet sponsor:

myriad

Conflict of Interest Disclosures

All presenters are required to disclose any conflicts of interest (COI) related to their presentation.

To view COI disclosures, visit **www.nsgc.org/conferencedisclosures**.

Sponsored Sessions

Sponsored meal sessions require pre-registration. If you pre-registered to attend a session, a ticket was printed with your badge. To be admitted to each session, please bring your conference badge and the ticket that pertains to that session. We encourage you to arrive early for each session to allow all attendees time to be seated. If you did not pre-register for a session but are still interested in attending, please visit the registration desk to check availability for each session.

Please note that because quantities are limited, not all attendees will receive food and beverage with their admittance. Please check your ticket to see whether the sponsor will provide food, or if you are encouraged to bring your own.

Executive Office Information

NSGC Executive Office
330 N. Wabash Avenue, Suite 2000
Chicago, IL 60611 USA
Phone: 312.321.6834
Email: nsgc@nsgc.org
Website: www.nsgc.org

Executive Director
Meghan Carey
mcarey@nsgc.org

BAYLOR
GENETICS

We pioneered the history of genetic testing. Now, we're leading the way in precision medicine.

For nearly 40 years, Baylor Genetics has been the leading pioneer in genetic testing. Now, we offer a full spectrum of cost-effective genetic testing and provide clinically relevant solutions. Our team's unmatched knowledge and experience deliver a combination of advanced technology and deep patient data sets that lead to more accurate interpretations.

// baylorgenetics.com

Schedule-At-A-Glance

KEY:

- Registration and Breaks
- Pre-conference Symposia
- Plenary Sessions
- NSGC Committee, SIG and Leadership Activities
- Exhibitor Suite
- Concurrent Papers/Poster Presentation
- Educational Breakout Sessions and Workshops
- Sponsored Sessions
- Program Reunions
- Organizational Events

WEDNESDAY, NOVEMBER 14

7:00 am – 8:00 pm	**Registration Open** | *Hall C1 Foyer*					
8:00 am – 2:00 pm	CEU **Pre-conference Symposia** | *Pre-registration required*					
	A01: A Collaborative View of Genomic Variant Interpretation: Clinical Genetic Counselors, Laboratories and Patients *Room C202-204*	**A02:** Advanced Motivational Interviewing Skills: Directional and Equipoise Guided Decision Making *Room C113*	**A03:** Ahead of the Curve: Genetic Counseling Strategies for Polygenic Risk of Breast Cancer *Room C112*	**A04:** Next Generation Prenatal Testing: Challenges, Utility and Application *Room C111*	**A05:** Professional Growth and Development for Laboratory Genetic Counselors *Room C208-210*	**A06:** The Art of Clinical Supervision: Developing and Enhancing Your Skills *Room C114*
10:00 am – 10:30 am	**Pre-conference Symposia Break** | *C100 Foyer and C200 Foyer*					
2:00 pm – 3:00 pm	**SIG Meetings**					
	Cancer SIG Meeting *Room C205*		**Education SIG Meeting** *Room C212*		**Neurogenetics SIG Meeting** *Room C211*	
2:00 pm – 3:15 pm	**Welcome to the Annual Conference: First-time Attendees** | *Room A411*					
2:00 pm – 3:15 pm	**NSGC SIG Fair** | *Room A412*					
3:30 pm – 3:45 pm	**Opening Remarks** | *Georgia Ballroom*					
3:45 pm – 4:15 pm	CEU **A07: Plenary Session: Adapt, Evolve and Thrive** | *Georgia Ballroom*					
4:15 pm – 4:45 pm	**Natalie Weissberger Paul National Achievement Award** | *Georgia Ballroom*					
4:45 pm – 5:15 pm	CEU **A08: Your Brave is Beautiful: An Artist's Campaign to Bring Empowerment and Advocacy to Those Diagnosed with Terminal Disease** | *Georgia Ballroom*					
5:30 pm – 8:30 pm	**Welcome Reception in Exhibitor Suite** | *Exhibit Hall C1/C2*					
5:45 pm – 7:00 pm	CEU **A09: Posters with Authors, Group A Posters** | *Exhibit Hall C1/C2*					
6:30 pm – 10:00 pm	**Various Program Reunions** | *See page 14 for more details*					
7:00 pm – 8:00 pm	**SIG Meetings**					
	ART/Infertility SIG Meeting *Room C206*	**Late Career SIG Meeting** *Room C212*	**Peds and Clinical SIG Meeting** *Room 201*	**Precision Medicine SIG Meeting** *Room C211*	**Cystic Fibrosis SIG Meeting** *Room C104*	
7:30 pm – 9:30 pm	***Journal of Genetic Counseling* Editorial Board Meeting** | *Room C104*					
8:00 pm – 9:00 pm	**Psychiatric SIG Meeting** | *Room C212*					

THURSDAY, NOVEMBER 15

6:30 am – 7:00 pm	**Registration Open** | *Hall C1 Foyer*	
7:00 am – 7:45 am	**Incoming NSGC Board and Committee Leadership Program** | *Room C211*	
7:00 am – 7:45 am	**SIG Leaders Breakfast** | *Room C206*	
7:00 am – 7:45 am	**NYMAC Regional Genetics Network** | *Room C201*	
7:00 am – 7:45 am	**Sponsored Breakfast Sessions**	
	CEU **B01:** Biochemistry and Base Pairs: How Global Metabolic Testing Contributes to Diagnosis and Discovery *Room A411* ***Sponsored by: Baylor Genetics***	**Termination of Pregnancy for Indications of Genetic Disorder in Advanced Gestations** *Room A412* ***Sponsored by: Boulder Abortion Clinic***

THURSDAY, NOVEMBER 15 (continued)

7:00 am – 7:45 am	**Public Policy Committee Meeting** | *Room C205*					
7:00 am – 8:00 am	**Conference Breakfast** | *Georgia Ballroom Foyer*					
8:00 am – 8:45 am	**Accreditation Council for Genetic Counseling (ACGC) Office Hours** | *Room C201*					
8:00 am – 8:35 am	CEU **B03: 2018 Janus Lecture** | *Georgia Ballroom*					
8:35 am – 9:35 am	CEU **B04: NSGC State of the Society Address** | *Georgia Ballroom*					
9:35 am – 10:05 am	**Incoming Presidential Address** | *Georgia Ballroom*					
10:05 am – 10:45 am	**Exhibitor Suite Open/Networking Break** | *Exhibit Hall C1/C2*					
10:45 am – 11:45 am	CEU **Educational Breakout Sessions**					
	B05: Genetic Counseling and LGBTQ Patients *Room C111*	**B06:** Inherited Prostate Cancer and Genetic Evaluation: Opportunities and Challenges in an Evolving Field *Georgia Ballroom*	**B07:** Clinical Variant Interpretation Beyond the Lab Report: Is it Part of Our Role and What is the Diversity in Our Practices? *Room C202-C204*	**B08:** Preimplantation Genetic Testing for Aneuploidy (PGT-A): What the Prenatal Genetic Counselor Needs to Know *Room C112*	**B09:** Promoting Genetic Counselors in Research: Funding Opportunities and Building a Research Portfolio *Room C113*	
11:45 am – 1:30 pm	**Exhibitor Suite Open** | *Exhibit Hall C1/C2*					
12:00 pm – 1:00 pm	**Committee Meetings**					
	Annual Conference Program Committee Meeting *Room C212*	**Marketing and Communications Workgroup Meeting** *Room C104*	**Membership Committee Meeting** *Room C201*	**Outcomes Committee Meeting** *Room C206*		
12:00 pm – 1:15 pm	**Sponsored Lunch Sessions**					
	CEU **B10:** Maximizing Genetic Testing Results for Hereditary Cancer Using RNA Studies *Room A411* ***Sponsored by: Ambry Genetics***		CEU **B11:** The Answer is in Your Genes: How Germline Status Now Informs Cancer Treatment Decisions *Room A412* ***Sponsored by: Myriad***			
12:15 pm – 1:15 pm	**Access and Service Delivery Committee Meeting** | *Room C205*					
12:30 pm – 1:30 pm	**Committee Meetings**					
	Education Committee Meeting | *Room C211*		**Practice Guidelines Committee Meeting** | *Room C207*			
1:15 pm – 1:45 pm	**Networking Break** | *C100 Foyer and C200 Foyer*					
1:45 pm – 3:45 pm	CEU **Workshops and Lectures** | **Pre-registration required*					
	B12: Collaborative and Efficient Service Delivery Models that Leverage Health Technology to Improve Access to Genetic Counseling *Georgia Ballroom*	***B13:** Helping Patients to Call on Their Resilience *Room C202-204*	***B14:** Learning to Lead: Becoming a Courageous Leader Through Self-assessment and Practical Application *Room C111*	***B15:** Peer Supervision: Revitalizing Your Genetic Counseling Career *Room C208-210*	***B16:** Referred a Pharmacogenetics Case, Now What? *Room C112*	***B17:** Supervision Evolution: Rethinking Student Rotations through the Industry Lens *Room C114*
3:45 pm – 4:15 pm	**Exhibitor Suite Open/Networking Break** | *Exhibit Hall C1/C2*					
4:15 pm – 5:20 pm	CEU **B18: Dr. Beverly Rollnick Memorial Lecture** | *Georgia Ballroom*					
5:20 pm – 5:50 pm	CEU **B19: Audrey Heimler Special Project Award Presentation** | *Georgia Ballroom*					
5:30 pm – 8:00 pm	**Exhibitor Suite Open** | *Exhibit Hall C1/C2*					
6:00 pm – 7:15 pm	CEU **B20: Posters with Authors, Group B Posters** | *Exhibit Hall C1/C2*					
7:00 pm – 10:00 pm	**Various Program Reunions** | *See page 14 for more details*					
7:15 pm – 8:30 pm	**Sponsored Evening Sessions**					
	CEU **B21:** Lola's Story: One Family's Journey with Prenatal Testing *Room A411* ***Sponsored by: Integrated Genetics***		CEU **B22:** NIPT: The Future is Now! *Room A412* ***Sponsored by: Illumina***			

Schedule-At-A-Glance (continued)

KEY:

- Registration and Breaks
- Pre-conference Symposia
- Plenary Sessions
- NSGC Committee, SIG and Leadership Activities
- Exhibitor Suite
- Concurrent Papers/Poster Presentation
- Educational Breakout Sessions and Workshops
- Sponsored Sessions
- Program Reunions
- Organizational Events

THURSDAY, NOVEMBER 15 (continued)					
7:30 pm – 8:30 pm	**Adrenoleukodystrophy Newborn Screening Roundtable Meeting** | *Room C104*				
7:30 pm – 8:30 pm	**Genomic Technology SIG Meeting** | *Room C212*				
FRIDAY, NOVEMBER 16					
7:00 am – 7:00 pm	**Registration Open** | *Hall C1 Foyer*				
7:00 am – 7:45 am	**Sponsored Breakfast Sessions**				
	CEU **C01:** Why it Matters: Screening for 21-OH Congenital Adrenal Hyperplasia *Room A411* ***Sponsored by: Counsyl***		CEU **C02:** Experience with Exome-based Panel Testing for Diseases with Prenatal or Neonatal Onset *Room A412* ***Sponsored by: Prevention Genetics***		
7:00 am – 7:45 am	**NSGC Past Board Member Breakfast** | *Room C212*				
7:00 am – 7:45 am	**SIG Meetings**				
	Cardiovascular SIG Meeting *Room C211*		**Leadership and Management SIG Meeting** *Room C104*		
7:00 am – 8:00 am	**Conference Breakfast** | *Georgia Ballroom Foyer*				
7:00 am – 8:45 am	**Accreditation Council for Genetic Counseling (ACGC) Office Hours** | *Room C201*				
8:00 am – 8:50 am	CEU **C03: Pre-test Counseling – Yay or Nay?** | *Georgia Ballroom*				
8:50 am – 9:05 am	CEU **C04: Best Full Member Abstract Award Presentation** | *Georgia Ballroom*				
9:05 am – 10:05 am	CEU **C05: Professional Issues Panel** | *Georgia Ballroom*				
10:05 am – 10:45 am	**Exhibitor Suite Open/Networking Break** | *Exhibit Hall C1/C2*				
10:45 am – 12:00 pm	CEU **Platform Presentations**				
	C06: Cancer Guidelines and Risk Assessment *Room C112*	**C07:** Counseling/ Psychosocial *Room C202-C204*	**C08:** Diversity and Access *Georgia Ballroom*	**C09:** Variant Interpretation and Diagnostics Utility *Room C111*	**C10:** Training and Workforce *Room C113*
12:00 pm – 1:30 pm	**Students Thesis Focus Group** | *Room C104*				
12:00 pm – 1:30 pm	**SIG Meetings**				
	Public Health SIG Meeting | *Room C201*	**Research SIG Meeting** | *Room C212*	**Student/New Member SIG Meeting** | *Room C206*		
12:00 pm – 3:00 pm	**Exhibitor Suite Open** | *Exhibit Hall C1/C2*				
12:15 pm – 1:15 pm	**Industry SIG Meeting** | *Room C211*				
12:15 pm – 1:30 pm	**Sponsored Lunch Sessions**				
	CEU **C11:** The Goldilocks Principle: Finding 'Just Right' in a World of Expanding Guidelines and Growing Access to Genetic Testing *Room A411* ***Sponsored by: Invitae***		CEU **C12:** The Art of Mosaic Variant Detection and Analysis: Laboratory Methods, Genetic Counseling Implications and Clinical Vignettes *Room A412* ***Sponsored by: GeneDx***		
12:30 pm – 1:30 pm	**American Board of Genetic Counseling (ABGC) Business Meeting** | *Georgia Ballroom*				
1:00 pm – 1:30 pm	**Accreditation Council for Genetic Counseling (ACGC) Presentation** | *Georgia Ballroom*				
1:30 pm – 2:45 pm	CEU **C13: Posters with Authors, Group C Authors** | *Exhibit Hall C1/C2*				
2:45 pm – 3:00 pm	**Passport to Prizes Drawing** | *NSGC Central Booth*				

FRIDAY, NOVEMBER 16 (continued)

3:10 pm – 4:40 pm	CEU **Educational Breakout Sessions**				
	C14: Immunodeficiencies and Bone Marrow Failure: What Every Genetic Counselor Should Know *Room C202-C204*	**C15:** It's in Our Veins: Evolving Issues in Counseling for Hereditary Hematologic Malignancies *Georgia Ballroom*	**C16:** New Developments in Testing Methods and Bioinformatics *Room C112*	**C17:** Population Sequencing and its Consequences: What Biobanks Can Teach Us About the Future of Genetic Testing *Room C113*	**C18:** What to Do When that Familial Disease Might Not Be So Familial After All: New Data on HCM and ARVC *Room C111*
4:40 pm – 5:00 pm	**Networking Break** | *Georgia Ballroom Foyer*				
5:00 pm – 5:45 pm	CEU **C19: Gene Therapy Has Arrived: Updates, FDA Approval, and Roles for Genetic Counselors** | *Georgia Ballroom*				
5:45 pm – 6:00 pm	CEU **C20: Beth Fine Best Student Abstract Award Presentation** | *Georgia Ballroom*				
6:00 pm – 6:30 pm	CEU **C21: Jane Engelberg Memorial Fellowship (JEMF) Presentation** | *Georgia Ballroom*				
6:30 pm – 7:30 pm	**Metabolism/LSG SIG Meeting** | *Room C104*				
6:45 pm – 8:45 pm	**2018 Code Talker Award Ceremony and Reception** | *Room A411-A412*				
7:00 pm – 9:00 pm	**American Board of Genetic Counseling (ABGC) Past Board Member Meeting** | *Room C206*				
7:00 pm – 10:00 pm	**Various Program Reunion** | *See page 14 for more details*				

SATURDAY, NOVEMBER 17

7:00 am – 7:45 am	**Sponsored Breakfast Sessions**	
	PGD for all Genetic Counseling Specialties: What You Want to Know for Your Patients *Room A411* ***Sponsored by: CooperGenomics***	CEU **D02:** Expanded Carrier Screening in Theory and Practice *Room A412* ***Sponsored by: Sema4***
7:00 am – 8:00 am	**Conference Breakfast** | *Georgia Ballroom Foyer*	
7:30 am – 12:00 pm	**Registration Open** | *Hall C1 Foyer*	
7:40 am – 1:00 pm	**Annual Conference Outreach Program** | *Room C205*	
8:05 am – 8:50 am	CEU **D03: Late-breaking Plenary Session: Have Polygenic Risk Scores Finally Arrived?** | *Georgia Ballroom*	
8:50 am – 9:50 am	CEU **D04: NHGRI: Establishing a 2020 Vision for Genetics** | *Georgia Ballroom*	
9:50 am – 10:10 am	**Networking Break** | *C100 Foyer and C200 Foyer*	

10:10 am – 11:40 am	CEU **Educational Breakout Sessions**				
	D05: Bringing Precision Medicine into the Oncology Clinic: Examples from Pediatric Somatic Tumor Testing *Georgia Ballroom*	**D06:** Conflict of Interest: We Are Stuck With It So How Should We Address It? *Room C112*	**D07:** Disorders of Sex Development (DSD): The Times Are Changing *Room C111*	**D08:** Sharing is Caring: Extending Shared Decision Making Principles into Genetic Counseling Practice *C202-C204*	**D09:** The Science of Surveys: Foundations of Survey Design and Implementation to Improve Genetic Counselor Research and Clinical Practice *Room C113*
12:00 pm – 1:15 pm	CEU **Platform Presentations**				
	D10: Service Delivery *Room C202-C204*	**D11:** Incidental and Unexpected Findings *Room C111*	**D12:** Neuromuscular/ Psychiatric *Room C113*	**D13:** ELSI *Room C208-C210*	**C14:** Cancer *Room C112*
6:00 pm – 7:00 pm	**HCM Review and Guidelines** | *Room C201*				

Convention Center Map






General/Plenary Session
Educational Breakout Sessions and SIG Meetings
Exhibit Hall, Registration, Educational Breakout Sessions and SIG Meetings
Building C
Level 3
Level 2
Level 1
Building B
Level 5
Level 4
Level 3
Level 2
Level 1
Building A
Level 4
Level 3
Level 1
Sponsored Meals and 2018 Code Talker Awards


Speaker Ready Room
General/Plenary Session
C301
C302
GEORGIA BALLROOM


EXECUTIVE BOARDROOM
Sidney J. Marcus AUDITORIUM
A401
A402
A403
A404
A405
A406
A407
A408
A409
A410
A412
A411
a
b
Outtakes
ENTRANCE
CFHOF Offices
Sponsored Meals and 2018 Code Talker Awards
Omni/Marietta St. Connector

Reunion Information

Please visit the NSGC Annual Conference mobile app for updated reunion information.

TIME	REUNION NAME	LOCATION
WEDNESDAY, NOVEMBER 14		
6:30 pm	**University of Oklahoma Health Sciences Center**	**Pittypat's Porch** 25 Andrew Young International Boulevard, Atlanta, GA 30303 | 404.525.8228
7:00 pm	**Long Island University (LIU) Post Genetic Counseling Graduate Program**	**Thrive Restaurant** 101 Marietta Street NW, 1st Floor Centennial Tower, Atlanta, GA 30303 | 404.389.1000
7:30 pm	**John Hopkins/NHGRI**	**Thrive Restaurant** 101 Marietta Street NW, 1st Floor Centennial Tower, Atlanta, GA 30303 | 404.389.1000
8:00 pm	**University of Maryland**	**Dantanna's Downtown** One CNN Center, Suite 269, Atlanta, GA 30303 | 404.522.8873
8:00 pm	**Stanford Genetic Counseling Program**	**STATS Brew Pub** 300 Marietta Street NW, Atlanta, GA 30313 | 404.885.1472
THURSDAY, NOVEMBER 15		
7:00 pm	**University of South Carolina**	**STATS Brew Pub** 300 Marietta Street NW, Atlanta, GA 30313 | 404.885.1472
7:00 pm	**Sarah Lawrence College**	**Room C211** Georgia World Congress Center, Atlanta, GA 30313
7:00 pm	**Boston University Genetic Counseling Program**	**Thrive Restaurant** 101 Marietta Street NW, 1st Floor Centennial Tower, Atlanta, GA 30303 | 404.389.1000
7:00 pm	**University of Alabama at Birmingham**	**Hudson Grille** 120 Marietta Street Atlanta, GA 30303 | 404.221.0102
7:15 pm	**Ichan School of Medicine at Mount Sinai**	**Sway at the Hyatt Regency** 320 Peachtree Street NE, Atlanta, GA 30303 | 404.460.6480
7:30 pm	**University of Pittsburgh Genetic Counseling Program**	**Ruth's Chris Steak House at the Embassy Suites** 267 Marietta Street NW, Atlanta, GA 30313 | 404.223.6500
7:30 pm	**Northwestern University Graduate Program in Genetic Counseling**	**Thrive Restaurant** 101 Marietta Street NW, 1st Floor Centennial Tower, Atlanta, GA 30303 | 404.389.1000
7:30 pm	**University of Texas**	**Max Lager's** 320 Peachtree Street NE, Atlanta, GA 30303 | 404.525.4400
7:30 pm	**University of Utah**	**Latitudes Bistro and Lounge** Omni Hotel, 100 CNN Center, Atlanta, GA 30303 | 404.659.0000
7:30 pm	**Indiana State University**	**Tentative Suite Food Lounge** 375 Luckie Street, Atlanta, GA 30313 | 404.577.2500
7:30 pm	**Emory University/Georgia Association of Genetic Counselors**	**Hudson Grille** 120 Marietta Street Atlanta, GA 30303 | 404.221.0102
8:00 pm	**University of Cincinnati Genetic Counseling Program**	**Dantanna's Downtown** One CNN Center, Suite 269, Atlanta, GA 30303 | 404.522.8873
8:00 pm	**CSU Stanislaus and UC Berkeley Genetic Counseling Programs**	**Agave Restaurant** 242 Boulevard SE, Atlanta, GA 30312 | 404.588.0006
8:30 pm	**University of Minnesota Genetic Counseling Program**	**Park Bar** 150 Walton Street NW, Atlanta, GA 30303 | 404.524.0444
FRIDAY, NOVEMBER 16		
7:00 pm	**University of Michigan Genetic Counseling Program**	**Fado's Irish Pub – Midtown** 933 Peachtree Street NE, Atlanta, GA 30309 | 404.260.7910
7:30 pm	**University of California, Irvine**	Location to be shared by email
9:00 pm	**Brandeis Genetic Counseling Program**	**Cafe Lucia** 57 Forsyth Street NW, Atlanta, GA 30303 | 678.424.1015

Session Speakers + Objectives

WEDNESDAY, NOVEMBER 14

Pre-conference Symposia

8:00 am – 2:00 pm

A01: A Collaborative View of Genomic Variant Interpretation: Clinical Genetic Counselors, Laboratories and Patients

5.0 Contact Hours

Karen Wain, MS, LGC, Geisinger; Emily Palen, MS, LGC, Geisinger; Ana Morales, MS, CGC, Ohio State University; Kami Wolfe Schneider, MS, CGC, University of Colorado, Children's Hospital Colorado; Kristy Lee, MS, CGC, University of North Carolina Chapel Hill; Jessica Mester, MS, LCGC GeneDx; Tina Pesaran, MS, MA, CGC, New York University; Sarah Barnett, CGC, Mayo Clinic; Casie Genetti, MS, CGC, Boston Children's Hospital; Amanda Buchanan, MS, CGC, Illumina; Juliann Savatt, MS, LGC, Geisinger

Moderator: Erin Rooney Riggs, MS, CGC

- Examine how genetic counselors are currently incorporating variant interpretation into their practice.
- Discuss evidence to gather and resources to use in different clinical scenarios.
- Examine how collaboration between clinicians, laboratories and patients can impact variant interpretation improvements.
- Discuss ways to incorporate variant interpretation principles and genomic resources into clinical workflow.

Attendance Verification Code: _____

A02: Advanced Motivational Interviewing Skills: Directional and Equipoise Guided Decision Making

5.0 Contact Hours

Erin Ash, MS, LCGC, Joan H. Marks Graduate Program in Human Genetics; Scott Walters, PhD, University of North Texas Health Science Center

- Identify the four processes of Motivational Interviewing (MI) conversations.
- Describe strategies for equipoise and directional counseling for decision making in different genetic counseling encounters.
- Apply MI strategies (e.g., rulers, values) to genetic counseling decision making.
- Plan application of decision making strategies to current practice.

Attendance Verification Code: _____

A03: Ahead of the Curve: Genetic Counseling Strategies for Polygenic Risk of Breast Cancer

5.0 Contact Hours

Montserrat Garcia-Closas, MD, MPH, DrPH, National Cancer Institute, Cancer Epidemiology & Genetics; Sara Pirzadeh-Miller, MS, UT Southwestern Medical Center; Barry Tong, MS, MPH, LCGC, UC San Francisco Medical Center; Diana De Rosa, MS, CGC, UC San Diego Health; Mary Helen Black, PhD, MS, Ambry Genetics; Jeffrey Tice, MD, University of California, San Francisco; Jennifer Saam, CGC PhD, Myriad Genetic Laboratories

- Explain the single nucleotide polymorphisms composition of a polygenic risk score for breast cancer, its multiplicative algorithm and validation, if any.
- Contrast methodologies for combining a polygenic risk with a risk model software and calculators.
- Critique current breast cancer polygenic risk offerings.
- Formulate counseling techniques and strategies for explaining polygenic risk for breast cancer to patients and healthcare providers.
- Identify medical management recommendations for women based on polygenic risk for breast cancer in the context of competing clinical factors.

Attendance Verification Code: _____

A04: Next Generation Prenatal Testing: Challenges, Utility and Application

5.0 Contact Hours

Neeta L. Vora, MD, University of North Carolina School of Medicine; Kelly E. Ormond, MS, CGC, LGC, Stanford University; Alice Tanner, PhD, CGC, PerkinElmer Genomics; Connie Schultz, MS, CGC

Moderators: Lori Dobson, MS, CGC; Katie Krepkovich, MS, MS, CGC; Lauren Lichten, MS, CGC

- Describe the development of panel testing to reflect clinical needs.
- Identify key components of successful panel selection in the setting of a fetal anomaly.
- Illustrate the utility of whole exome testing in the setting of a fetal anomaly.
- Describe the challenges of whole exome testing in the setting of a fetal anomaly.
- Demonstrate how to successfully interpret genetic variants detected through fetal next generation testing.
- Review the unique aspects of variant interpretation in a prenatal setting.
- Illustrate the psychological complexities for patients undergoing genomic testing in a prenatal setting.
- Employ counseling skills to empower patients dealing with uncertainty during pregnancy.
- Apply knowledge of prenatal genomic testing through scientific case discussion.
- Integrate new psychosocial skills into counseling-based case discussion.

Attendance Verification Code: _____

Session Speakers + Objectives (continued)

A05: Professional Growth and Development for Laboratory Genetic Counselors

5.0 Contact Hours

Pat McCarthy Veach, PhD, LP, University of Minnesota; Krista Redlinger Grosse, PhD, LP, ScM, CGC, University of Minnesota; Christine Miller, MS, LCGC, ARUP Laboratories; Christina Zaleski, MS, CGC, PreventionGenetics; McKinsey Goodenberger, MS, LCGC, Mayo Clinic; Sarah Clowes Candadai, MS, LCGC, Seattle Children's Hospital; Jacquelyn Riley, MS, LCGC, Cleveland Clinic

Moderator: Jordan Elliott Bontrager, MS, LCGC

- Establish personal goals for professional growth and development in laboratory genetic counseling.
- Link personal goals for professional growth and development to strategies for goal attainment.
- Identify strategies for promoting professional growth and development in laboratory genetic counseling.
- Distinguish potential benefits and challenges of personal motivations on one's work as a laboratory genetic counselor.
- Identify factors that influence laboratory genetic counselor professional growth and development.

Attendance Verification Code: _____

A06: The Art of Clinical Supervision: Developing and Enhancing Your Skills

5.0 Contact Hours

Bonnie LeRoy, MS, LGC, University of Minnesota; Angie Trepanier, MS, CGC, Wayne State University; Chris Peltier, MD, FAAP, Cincinnati Children's Hospital Medical Center; Katie Wusik, MS, LGC, Cincinnati Children's Hospital Medical Center

Moderator: Carrie Atzinger, MS, CGC

- Discuss the genetic counseling supervision competencies and how they can guide supervision practice.
- Describe models of supervision that can be used to frame supervision practice and approaches to feedback in genetic counseling training.
- Demonstrate feedback methods including the "Ask Tell, Ask Teach" approach.
- Utilize the RIME framework to set developmentally appropriate expectations for students in various stages of training and for evaluating student achievement of the ACGC practice-based competencies.

Attendance Verification Code: _____

Plenary Sessions

3:45 pm – 4:15 pm

A07: Adapt, Evolve and Thrive

0.50 Contact Hour

Dana M. Knutzen, MS, CGC, Baylor College of Medicine, The Children's Hospital of San Antonio; Nadine Channaoui, MS, CGC, Brigham and Women's Hospital; Shivani Nazareth, MS, CGC, Clear Genetics

- Examine ways that three genetic counselors have adapted, evolved and thrived within their careers.
- Illustrate strategies for successful genetic counselor career adaptation and evolution.
- Discuss our shared genetic counseling skills, history and core values.

Attendance Verification Code: _____

4:45 pm – 5:15 pm

A08: Your Brave is Beautiful: An Artist's Campaign to Bring Empowerment and Advocacy to Those Diagnosed with Terminal Disease

0.50 Contact Hour

Chantae Cann, Atlanta Records

- Identify the various psychosocial implications of living at risk of Huntington disease (HD).
- Describe the experience of a patient with HD in her family as she navigates the decisions around pre-symptomatic testing and whether to proceed with testing, ultimately using her positive test result to help patients feel empowered by their choices.

Attendance Verification Code: _____

THURSDAY, NOVEMBER 15, 2018

Sponsored Breakfast Sessions

7:00 am – 7:45 am

B01: Biochemistry and Base Pairs: How Global Metabolic Testing Contributes to Diagnosis and Discovery

0.50 Contact Hour

Sarah H. Elsea PhD, FACMG, Baylor College of Medicine

- Define global metabolomic testing.
- Explain how the use of global metabolomic technology complements and expands the reach of whole exome sequencing in terms of functional analysis of genetic variants.
- Provide examples of new biomarker and genetic variant discoveries highlighting how these examples bridge the gap between research and clinical studies.

Sponsored by: BAYLOR GENETICS

Attendance Verification Code: _____

Termination of Pregnancy for Indications of Genetic Disorder in Advanced Gestations

Cathernie Chalecki, Boulder Abortion Clinic

- Describe the relevance of these services to genetics.

- Identify the purpose, basic principles and components of clinical practice including grief support.
- Outline the basic operative procedures and clinical results of this care.

Sponsored by:

BOULDER ABORTION CLINIC

Attendance Verification Code: _____

Plenary Sessions

8:00 am – 8:35 am

B03: 2018 Janus Lecture

0.50 Contact Hour

Jodie Ingles, BiomedSci, GradDipGenCouns, PhD, MPH, Centenary Institute & University of Sydney

- Describe the role of genetic counselors in the management of families with inherited cardiovascular diseases.
- Understand the limitations of our current knowledge and where research is needed to provide a greater evidence base for the care of families.

Attendance Verification Code: _____

8:35 am – 9:35 am

B04: NSGC State of the Society Address

1.0 Contact Hour

Erica Ramos, MS, LCGC

- Describe the activities of NSGC over the past year as related to the advancement of the profession of genetic counseling.
- Assess NSGC's advocacy efforts over the course of 2018.
- Identify opportunities for supporting diversity and inclusion in the profession of genetic counseling.

Attendance Verification Code: _____

9:35 am – 10:05 am

Incoming Presidential Address

Amy Sturm, MS, CGC, LGC

- Welcome NSGC President-Elect Amy Sturm, as she introduces herself to NSGC members and outlines her vision for NSGC and the genetic counseling profession in 2019.

Educational Breakout Sessions

10:45 am – 11:45 am

B05: Genetic Counseling and LGBTQ Patients

1.0 Contact Hour

Erica Smith, MEd, The Children's Hospital of Pennsylvania, QSpaces; Diane Koeller, MS, MPH, LCGC, Dana-Farber Cancer Institute; Rosalba Sacca, PhD, CGC, Memorial Sloan-Kettering Cancer Center

Moderator: Andrea Forman, MS, LCGC

- Review terms and concepts and health disparities related to the LGBTQ community.
- Identify particular challenges within the transgender community, e.g. reproductive choices, hereditary cancer risk, pedigree nomenclature.
- Explore emerging challenges in clinical care for the LGBTQ community, including health, legal and advocacy issues.

Attendance Verification Code: _____

B06: Inherited Prostate Cancer and Genetic Evaluation: Opportunities and Challenges in an Evolving Field

1.0 Contact Hour

Veda N. Giri, MD, Sidney Kimmel Cancer Center, Thomas Jefferson University; Mary-Ellen Taplin, MD, Dana-Farber Cancer Institute, Harvard Medical School; Colette Hyatt, MS, LCGC, Sidney Kimmel Cancer Center at Thomas Jefferson University

- Summarize the risk for prostate cancer conferred by genes on current multigene panels.
- State knowledge of current guidelines regarding prostate cancer screening and emerging management informed by genetic results.
- List the considerations in genetic counseling for males concerned about inherited prostate cancer and strategies to link counseling with clinical care.
- Summarize considerations of tumor testing in men with metastatic prostate cancer for targeted therapy.

Attendance Verification Code: _____

B07: Clinical Variant Interpretation Beyond the Lab Report: Is it Part of Our Role and What is the Diversity in Our Practices?

1.0 Contact Hour

Carol Saunders, PhD, Children's Mercy Kansas City; Emily Farrow, PhD, CGC, Children's Mercy Kansas City; Chloe Reuter, MS, LCGC, Stanford Center for Inherited Cardiovascular Disease; Whitney Ford, MS, CGC, Saint Luke's Cancer Institute; Carolyn Dinsmore Applegate, MGC, CGC, Johns Hopkins University; Megan Tucker, CGC, LGC, Indiana State University

Moderator: Courtney Berrios, MSc, ScM, CGC

- Identify reasons for variable interpretation of genetic variants by laboratories.
- Summarize the variability in genetic counselor practices for clinical genetic test result interpretation.
- Evaluate personal processes and attitudes about variant interpretation in clinical testing in comparison to other genetic counselors.

Attendance Verification Code: _____

Session Speakers + Objectives (continued)

B08: Preimplantation Genetic Testing for Aneuploidy (PGT-A): What the Prenatal Genetic Counselor Needs to Know

1.0 Contact Hour

Jamie K. Dokson, ScM, LCGC, Reproductive Biology Associates; Andria Besser, MS, CGC, NYU Langone Fertility Center; Alyssa Snider, MS, PhD, LCGC, Igenomix, USA; Rachel Silver, ScM, CGC, CCGC, Mount Sinai Hospital Prenatal Diagnosis & Medical Genetics

- Describe crucial tenets of a PGT-A counseling session including: the indications for PGT-A; the biopsy procedure and risks; test platforms; test limitations; and clinical significance of PGT-A results.
- Compare and contrast the significance of "abnormal" chromosome results identified in the preimplantation vs. prenatal period.
- Review the latest data regarding outcomes of mosaic embryo transfers.
- Describe key considerations regarding prenatal testing following PGT-A.
- Formulate an appropriate prenatal counseling plan for their patients who are pregnant following the transfer of euploid and mosaic embryos.

Attendance Verification Code: _____

B09: Promoting Genetic Counselors in Research: Funding Opportunities and Building a Research Portfolio

1.0 Contact Hour

Dave Kaufman, PhD, National Human Genome Research Institute; Cynthia James, PhD, ScM, PhD, Johns Hopkins University; Jodie Ingles BiomedSci, GradDipGenCouns, PhD, MPH, Centenary Institute & University of Sydney

- Identify grant opportunities for funding genetic counseling research at organizational, institutional and national levels.
- Examine grant writing processes including choosing funding that fits the project, collecting pilot data, drafting specific aims and building a research team.
- Review strategies to strengthen one's research portfolio and effectively promote one's skills and expertise related to research.

Attendance Verification Code: _____

Sponsored Lunch Sessions

12:00 pm – 1:15 pm

B10: Maximizing Genetic Testing Results for Hereditary Cancer Using RNA Studies

1.00 Contact Hour

Rachid Karam MD, PhD, Ambry Genetics

- Explain basic information about the role of RNA studies in the detection of rare mutations and variant classification.
- Explain key findings from the experience of one laboratory with utilizing RNA studies to improve variant classification.
- Discuss specific case examples of variant resolution with RNA studies.

Sponsored by: Ambry Genetics® A Konica Minolta Company

Attendance Verification Code: _____

B11: The Answer is in Your Genes: How Germline Status Now Informs Cancer Treatment Decisions

1.00 Contact Hour

Jennifer Saam, PhD, Myriad

- Examine recent medical advances that have resulted in the need for germline status when determining the best cancer treatment options.
- Discuss the challenges and advantages germline test results influencing treatment decisions may pose for clinical genetic counselors.
- Highlight novel strategies deployed by genetic counselors in partnering with physicians to integrate germline testing into the treatment decision making process.

Sponsored by: myriad®

Attendance Verification Code: _____

Workshops and Lectures

1:45 pm – 3:45 pm

B12: Collaborative and Efficient Service Delivery Models that Leverage Health Technology to Improve Access to Genetic Counseling

2.0 Contact Hours

No pre-registration required

Stephanie A. Cohen, MS, LCGC, St. Vincent Health; Brian Reys, MS, CGC, UT Southwestern; Megan Frone, MS, CGC, National Cancer Institute, National Institutes of Health; Courtney Cook, MS, LCGC, Highlands Oncology Group; Hilary Kershberg, MS, LCGC, Southern California Permanente Medical Group; Gayle Patel, MS, CGC, Texas Oncology

Moderator: Christina Delaney, MS, CGC

- Define service delivery models (SDMs) in genetic counseling.
- Identify health technology resources that can be incorporated into SDMs to improve efficiency.
- Identify barriers and resources to implementation of innovative SDMs.
- Characterize outcomes measures to document successes and opportunities for improvement of current and new SDMs.
- Describe how genetic counselors use collaborative SDMs to increase access for patients.

Attendance Verification Code: _____

B13: Helping Patients to Call on Their Resilience

2.0 Contact Hours

Erin Ash, MS, LCGC, Joan H. Marks Graduate Program in Human Genetics; Julia Platt, MS, LCGC, Stanford Center for Inherited Cardiovascular Disease; Karen Hurley, PhD, Cleveland Clinic

Moderator: Tia Moscarello, MSc, CGC

- Define resilience and list factors that research has found to be associated with resilience.
- Describe how to assist genetic counseling clients in leveraging their own inherent resilience.
- Use three specific techniques to facilitate resilience in your own clinical practice: identification and application of strengths, activation of specific social support and crafting self-coaching statements.

Attendance Verification Code: _____

B14: Learning to Lead: Becoming a Courageous Leader Through Self-assessment and Practical Application

2.0 Contact Hours

Leah Williams, MS, CGC, GeneDx; Melanie Hardy, MS, MS, LCGC, Emory University; Holly Taylor, MS, CGC, GeneDx; Leslie Bucheit, MS, CGC, Counsyl; Patricia Page, MS, LCGC, The University of Alabama at Birmingham; Nancy Palmer, MS, CGC, Maternal & Fetal Specialty Center, Swedish Medical Center

- Describe various leadership assessment tools and their potential application in genetic counseling teams.
- Identify leadership qualities inherent to the workshop attendee.
- Develop a solution to a leadership/management problem using leadership qualities both inherent and not inherent to the attendee.
- Evaluate the impact of differing leadership styles on team problem-solving capabilities.
- Assess leadership and management challenges of the individual workplace using the skills identified in the workshop.
- Develop team engagement and accountability by incorporating ideas from individuals of all personality qualities.

Attendance Verification Code: _____

B15: Peer Supervision: Revitalizing Your Genetic Counseling Career

2.0 Contact Hours

Barbara Fairfeld, LCMFT, Johns Hopkins University Hospital; Colleen Caleshu, MS, LCGC, Stanford Center for Inherited Cardiovascular Disease; Gretchen MacCarrick, MS, CGC, Johns Hopkins University; Lauren Lichten, MS, CGC, Brandeis University

Moderator: Katelynn G. Sagaser, MS, CGC

- Examine clinical counseling techniques relevant to the facilitation of genetic counselor peer supervision groups.
- Review benefits and challenges of genetic counseling peer supervision groups.
- Identify strategies for group formation and for supervision methods to meet the needs of the group and its members.
- Apply counseling skills to small group supervision cases of challenging professional and patient issues.

Attendance Verification Code: _____

B16: Referred a Pharmacogenetics Case, Now What?

2.0 Contact Hours

Rachel Mills, MS, CGC, Duke Center for Applied Genomics & Precision Medicine; Heather Zierhut, PhD, MS, University of Minnesota

- Recognize patient care situations that could benefit from pharmacogenetics (PGx) testing.
- Identify disease associations that are secondary findings of PGx panels.
- Review common examples of PGx cases that arise in general genetics, oncology, psychiatry and cardiology clinical care.

Attendance Verification Code: _____

B17: Supervision Evolution: Rethinking Student Rotations through the Industry Lens

2.0 Contact Hours

MaryAnn W. Campion, EdD, MS, LCGC, Stanford University; Tara R. Hart, MS, CGC, GeneDx; Kate L. Wilson, MS, CGC, Quest Diagnostics; Molly McGinniss, MS, LCGC, Illumina; McKinsey Goodenberger, MS, LCGC, Mayo Clinic; Stacie Rosenthal, MS, CGC, Counsyl

Moderator: Kate Wilson, MS, CGC

- Illustrate the need for genetic counseling student exposure to industry roles based on current and expected workforce stats.
- Summarize the current charge of the ACGC Standards Committee to revise the Standards for Accreditation and how that will influence demand for industry rotations.
- Evaluate how potential industry sites can work with genetic counseling programs to implement a new rotation site while managing conflict of interest.
- Construct industry rotation learning objectives and curriculum utilizing lessons learned from current industry-based genetic counseling supervisors.

Attendance Verification Code: _____

Plenary Sessions

4:15 pm – 5:20 pm

B18: Dr. Beverly Rollnick Memorial Lecture: The Mutant Diaries: Unzipping My Genes

1.00 Contact Hour

Eva Moon, The Mutant Diaries

- Illustrate how using humor and art can help some patients cope with stress and crisis.

Session Speakers + Objectives (continued)

- Examine the lived patient experience during the delivery of a genetic diagnosis.

Attendance Verification Code: _____

5:20 pm – 5:50 pm

B19: Audrey Heimler Special Project Award Presentation

0.50 Contact Hour

Carrie Atzinger, MS, LGC, Cincinnati Children's Hospital and University of Cincinnati Genetic Counseling Program; Katherine Wusik Healy, LGC, Cincinnati Children's Hospital Medical Center

- Describe the recruitment of participants and data analysis approach for a study of genetic counseling supervision as it is currently practiced.
- Discuss the Reciprocal Engagement Model of Supervision and what aspects of it are demonstrated in supervision meetings between students and supervisors.

Attendance Verification Code: _____

Sponsored Evening Sessions

7:15 pm – 8:30 pm

B21: Lola's Story: One Family's Journey with Prenatal Testing

1.00 Contact Hour

Erica Soster, MS, LCGC, Lab Corp; Lisa Phillips-Stackman; Jackie Phillips-Stackman

- Illustrate the clinical journey and genetic testing process that led to Lola's diagnosis.
- Examine the psychosocial journey that Lola's parents faced throughout the process.
- Evaluate the emotional, social, and legal forces involved in Lola's journey.

Sponsored by: Integrated GENETICS, LabCorp Specialty Testing Group

Attendance Verification Code: _____

B22: NIPT: The Future is Now!

1.00 Contact Hour

Elene Ashkinadze, MS, CGC, Rutgers Health; Lorraine Dugoff, MD, The Hospital of the University of Pennsylvania

- Outline the basic principles of screening for chromosomal imbalance during pregnancy using cell-free DNA (cfDNA) and how it can be tested to determine the risk of fetal aneuploidy through microarray technology.
- Assess the relative benefits and limitations of first and second trimester technologies, clinical utilization of NIPT and integration into practice.
- Discuss the impact of cfDNA testing on the evolution of maternal serum testing.
- Discuss available treatment options after early detection of genetic disorders.

Sponsored by: illumina

Attendance Verification Code: _____

FRIDAY, NOVEMBER 16

Sponsored Breakfast Sessions

7:00 am – 7:45 am

C01: Why it Matters: Screening for 21-OH Congenital Adrenal Hyperplasia

0.50 Contact Hour

Allison Goetsch, MS, CGC, Ann & Robert H. Lurie Children's Hospital of Chicago; Jamie Kostialik, MS, CGC, Counsyl; Dale Muzzy, PhD, Counsyl

- Understand the clinical presentation of 21-OH Congenital Adrenal Hyperplasia.
- Appreciate the complexities of testing for genetic conditions with pseudogenes.
- Identify the impact of early diagnosis of disease on treatment decisions.

Sponsored by: Counsyl

Attendance Verification Code: _____

C02: Experience with Exome-based Panel Testing for Diseases with Prenatal or Neonatal Onset

0.50 Contact Hour

Connie Schulz, MS, CGC, Prevention Genetics; Megan Nelson, MS, CGC, Prevention Genetics

- Develop a better understanding of molecular genetic testing methodologies and identify appropriate testing strategies.
- Become familiar with the benefits and limitations of exome-based panel testing.
- Gain insight into one laboratory's experience with exome-based panel testing for disorders that present in the prenatal or neonatal time period.

Sponsored by: PREVENTION GENETICS, DISEASE PREVENTION THROUGH GENETIC TESTING

Attendance Verification Code: _____

Plenary Session

8:00 am – 8:50 am

C03: Pre-test Counseling – Yay or Nay?

0.50 Contact Hour

Gillian Hooker, PhD, ScM, LCGC, Concert Genetics; Shanna Gustafson, MS, MPH, LGC, InformedDNA; Julie Cohen, ScM, CGC, Kennedy Krieger Institute; Kristin Price, MS, CGC, Counsyl; Heather Zierhut, PhD, University of Minnesota; Kaylene Ready, MS, CGC, Counsyl

- Describe the evidence in support of pre-test genetic counseling for some patient groups.
- Compare and contrast the evidence that pre-test genetic counseling requirements limit access to genetic counseling for some patient groups.

Attendance Verification Code: _____

Best Full Member Abstract Award Presentation

8:50 am – 9:05 am

C04: Group Telehealth Appointments for Cancer Counseling Increase Genetic Counselor Efficiency

0.25 Contact Hour

Renee Rider, JD, MS, LGCG, Department of Veterans Affairs

- Describe two benefits, one for providers and one for patients, of a genetic counseling program that uses group telehealth appointments to care for patients with family histories of cancer.

Attendance Verification Code: _____

Professional Issues Panel

9:05 am – 10:05 am

C05: Professional Issues Panel

1.00 Contact Hour

John Richardson, NSGC; Erica Joy Baker, Patreon and Project Include

Moderator: Erica Ramos, MS, CGC

- Describe the activities of NSGC over the past year as related to the advancement of the profession of genetic counseling.
- Summarize the action steps that promote and maintain a culture of diversity and inclusion.
- Identify opportunities for supporting diversity and inclusion in the profession of genetic counseling.

Attendance Verification Code: _____

Sponsored Lunch Sessions

12:15 pm – 1:30 pm

C11: The Goldilocks Principle: Finding 'Just Right' in a World of Expanding Guidelines and Growing Access to Genetic Testing

0.50 Contact Hour

Teresa Kruisselbrink, LCGC, Mayo Clinic; Jamie K. Dokson, ScM, LCGC

- Explain the evolution of guidelines and how they have transformed genetic risk evaluations and testing.
- Discuss the clinical impact when recent data and guidelines conflict.
- Examine the utility of proactive genetic testing in healthy populations outside of current guidelines.

Sponsored by: INVITAE

Attendance Verification Code: _____

C12: The Art of Mosaic Variant Detection and Analysis: Laboratory Methods, Genetic Counseling Implications and Clinical Vignettes

0.50 Contact Hour

Dinalee McNight, PhD, FACMG, GeneDx; Rebecca Torene, PhD, MMSc, GeneDx; Elizabeth Butler, MS, CGC, GeneDx

- Review the biology of mosaicism in patients and parents.
- Summarize the frequency of mosaicism by disease categories and highlight disease genes with high mosaic rates.
- Discuss detection of parental mosaicism, clinical presentations, and recurrence risk adjustments.

Sponsored by: GeneDx an OPKO Health Company

Attendance Verification Code: _____

Educational Breakout Sessions

3:10 pm – 4:40 pm

C14: Immunodeficiencies and Bone Marrow Failure: What Every Genetic Counselor Should Know

1.50 Contact Hours

Rebecca Tryon, MS, LGC, University of Minnesota Health; Britt Johnson, PhD, FACMG, Invitae; Jennifer Puck, MD, University of California San Francisco

Moderator: Leandra Tolusso, MS, LGC

- Summarize the unique aspects of the diagnosis and treatment of patients with primary immunodeficiencies (PIDs) and bone marrow failure syndrome (BMFS).

Session Speakers + Objectives (continued)

- Formulate a plan for addressing common psychosocial challenges in counseling patients with these conditions.
- Identify appropriate genetic testing options and sample types for patients with these conditions.
- Discuss experiences with PIDs and BMFS with other genetic counselors.

Attendance Verification Code: _____

C15: It's in Our Veins: Evolving Issues in Counseling for Hereditary Hematologic Malignancies

1.50 Contact Hours

Kaylee Barber, MS, CGC, BioReference/GenPath; Amy Knight Johnson, MS, CGC, Invitae; Courtney D. DiNardo, MD, University of Texas MD Anderson Cancer Center; Katherine A. Schneider, MPH, LGC, Dana-Farber Cancer Institute

Moderator: Sarah A. Jackson, MS, CGC

- From a hematopoietic perspective, explain the difference between AML and CLL.
- Select an appropriate specimen source to use for germline genetic testing, given a patient with a current or history of a specified hematologic malignancy.
- List three emerging genes in the field of hereditary hematologic malignancies.
- Explain how transplant donor selection may be impacted in the setting of hereditary hematologic malignancies.
- Describe a psychosocial situation that may be unique to an indication of hereditary hematologic malignancy susceptibility, as opposed to solid tumor susceptibility.

Attendance Verification Code: _____

C16: New Developments in Testing Methods and Bioinformatics

1.50 Contact Hours

Eric Klee, PhD, Mayo Clinic; Stephen Lincoln, Invitae; Brian Shirts, MD, PhD, University of Washington

Moderator: Samantha Baxter, MS, LCGC

- Assess current publications and guidelines regarding Sanger confirmation of next-generation sequencing (NGS) results, and determine which test approaches may be appropriate for your practice setting.
- Contrast the capabilities of emerging sequencing and copy-number methods with conventional NGS, Sanger and microarray testing.
- Distinguish procedures and reference databases used with somatic testing from those used with germline testing.
- Describe the clinical utility of using both tests together.
- Evaluate resources used with panel, exome and genome testing which can help facilitate collaborations and clarify gene-phenotype relationships, and potentially resolve variants of unknown significance.

Attendance Verification Code: _____

C17: Population Sequencing and its Consequences: What Biobanks Can Teach Us About the Future of Genetic Testing

1.50 Contact Hours

Maureen Smith, MS, LCGC, Northwestern University Feinberg School of Medicine; Liis Leitsalu, PhD, Estonian Genome Center of the University of Tartu; Carrie Blout, MS, CGC, LGC, Brigham and Women's Hospital; Erin Winkler, MS, LCGC, Mayo Clinic; Sharon Aufox, MS, Northwestern University; Marci Schwartz, ScM, LGC, Geisinger; Jill Stopfer, MS, LGC, Dana-Farber Cancer Institute; Katherine Blizinsky, PhD, National Institutes of Health

Moderator: Carrie Blout, MS, CGC, LGC

- Describe the role that genetic counselors play in returning unanticipated results to biobank participants, often in the absence of pre-test counseling.
- Describe and compare the various components of US and non-US biobanks.
- Define the various roles of genetic counselors with biobanks.
- Describe important genetic counseling biobank considerations, including cascade testing and notification of the relatives of deceased participants.

Attendance Verification Code: _____

C18: What to Do When that Familial Disease Might Not Be So Familial After All: New Data on HCM and ARVC

1.50 Contact Hours

Jodie Ingles, BiomedSci, GradDipGenCouns, PhD, MPH, Centenary Institute & University of Sydney; Cynthia James, ScM, PhD, CGC, Johns Hopkins University; Allison Cirino, MS, LGC, Brigham and Women's Hospital; Matthew Thomas, ScM, CGC, University of Virginia Health System

Moderator: Katherine Spoonamore, MS, LCGC

- Identify how emerging research findings challenge conventional understanding of the inheritance pattern and etiology of HCM and ARVC.
- Apply new evidence about the genetic basis of HCM and ARVC in clinic to improve anticipatory guidance regarding likelihood a pathogenic variant will be detected.
- Consider the role of genetic counselors in risk communication where familial inheritance is in doubt.
- Plan how to use this data to inform cascade testing and clinical surveillance of relatives.

Attendance Verification Code: _____

Plenary Session

5:00 pm – 5:45 pm

C19: Gene Therapy Has Arrived: Updates, FDA Approval, and Roles for Genetic Counselors

0.66 Contact Hour

Dana Schlegel, MS, MPH, CGC, Michigan Medicine Kellogg Eye Center; Melissa Gibbons, MS, CGC, University of Colorado SOM/Children's Hospital Colorado

- Identify several gene-based therapy trials and why the eye is a particularly good model for gene therapy delivery and clinical trials.
- Differentiate the historical use of gene therapy from the current use of clinical trials for gene therapy and the recent FDA approval of one of these treatments.

Attendance Verification Code: _____

Beth Fine Kaplan Student Abstract Award Presentation

5:45 pm – 6:00 pm

C20: Ethnic Disparities in the Frequency of Cancer Reported in Family Histories

0.25 Contact Hour

Heather Maves, MS, MB (ASCP), Integrated Genetics

- Raise awareness with data that some ethnicities may be at higher risk for providing truncated family histories regarding cancer reporting to healthcare professionals.
- Inspire consideration of options for healthcare professionals to assist families with truncated histories to help optimize healthcare.

Attendance Verification Code: _____

6:00 pm – 6:30 pm

C21: Jane Engelberg Memorial Fellowship (JEMF) Presentation

0.50 Contact Hour

Dawn Allain, MS, LGC, The Ohio State University Genetic Counseling Graduate Program; Brittney Murray, MS, CGC, Johns Hopkins Hospital

- Review the history of the JEMF award and provide an update on current initiatives.
- Recognize barriers in starting a telemedicine service within an existing clinic.
- Analyze the outcomes and impact of genetic counseling within the inherited cardiovascular disease clinic.

Attendance Verification Code: _____

SATURDAY, NOVEMBER 17

Sponsored Breakfast Sessions

7:00 am – 7:45 am

PGD for all Genetic Counseling Specialties: What You Want to Know for Your Patients

Rachel Cabey, MS, LGC, CooperSurgical

- Review the technology and procedures used for PGD.
- Describe requirements needed to proceed with a PGD case (documentation, testing, etc.).
- Discuss case examples to demonstrate practical application.

Sponsored by: CooperGenomics℠ a CooperSurgical company

Attendance Verification Code: _____

D02: Expanded Carrier Screening in Theory and in Practice

0.50 Contact Hour

Lisa Edelmann, PhD, FACMG, Sema4 and Icahn School of Medicine

- Discuss the history of carrier screening including the development of expanded carrier screening (ECS) panels.
- Critically assess the advantages and limitations of full gene sequencing in carrier screening.
- Review advantages of performing ECS in all populations, regardless of ethnicity.
- Recognize that accurate risk assessment and genetic counseling is dependent on assessing the detection rate and residual risk for the specific ECS panel used as well as knowledge of the patient's personal and family history.

Sponsored by: sema4 a Mount Sinai venture

Attendance Verification Code: _____

Late-breaking Plenary Session

8:05 am – 8:50 am

D03: Have Polygenic Risk Scores Finally Arrived?

0.75 Contact Hour

Laura Hercher, MSGC, Sarah Lawrence College Joan H. Marks Graduate Program in Human Genetics; Ali Torkamani, PhD, Scripps Research

- Describe the composition and construction of polygenic risk scores.
- Illustrate current and potential applications of polygenic risk scores.
- Appraise the relative clinical value of a polygenic risk score.

Attendance Verification Code: _____

Session Speakers + Objectives (continued)

8:50 am – 9:50 am

D04: NHGRI: Establishing a 2020 Vision for Genetics

1.00 Contact Hour

Carla Easter, PhD, National Human Genome Research Institute; Leslie G. Biesecker, MD, National Human Genome Research Institute

- Describe the activities involved in the NHGRI 2020 strategic planning process.
- Describe the five topical focus areas of the strategic planning process.
- Distinguish how the new strategic planning process will differ from prior processes in scope and breadth.
- Identify the opportunities to contribute to the NHGRI strategic planning process.

Attendance Verification Code: _____

Educational Breakout Sessions

10:10 am – 11:40 am

D05: Bringing Precision Medicine into the Oncology Clinic: Examples from Pediatric Somatic Tumor Testing

1.50 Contact Hours

Sarah Scollon, MS, CGC, Baylor College of Medicine, Texas Children's Cancer Center; Kami Wolfe Schneider, MS, CGC, University of Colorado, Children's Hospital Colorado; Joyce T. Turner, MS, CGC, Children's National Medical Center

- Recognize clinical scenarios in which tumor molecular testing may demonstrate clinical utility in the care of childhood cancer patients.
- Compare tumor-only and tumor-normal testing models in the oncology clinic.
- Identify ethical and psychosocial issues in implementing tumor molecular testing into the pediatric setting.

Attendance Verification Code: _____

D06: Conflict of Interest: We Are Stuck With It So How Should We Address It?

1.50 Contact Hours

Steven Keiles, MS, LCGC, Quest Diagnostics; Andrea Forman, MS, LCGC, Fox Chase Cancer Center; Robert Resta, MS, LCGC, Swedish Cancer Institute, Swedish Medical Center; Amy Curry Sturm, MS, LGC, Genome Medicine Institute, Geisinger

Moderator: Scott Weissman, MS, LCGC

- Explain the importance of identifying a real or perceived conflict of interest (COI) – financial and non-financial.
- Describe the circumstances in which COI might occur in the genetic counselor-patient encounter.
- Analyze various situations to determine if real or perceived COI might exist.

Attendance Verification Code: _____

D07: Disorders of Sex Development (DSD): The Times Are Changing

1.50 Contact Hours

Lauren Mohnach, MS, CGC, University of Michigan; Jullianne Diaz, MS, CGC, Children's National Health System; Jodie Johnson, LGC, Cincinnati Children's Hospital Medical Center

- Compare the historical and current management practices of patients with a Disorder of Sex Development (DSD).
- Identify the current controversies surrounding the care of individuals with a DSD.
- Summarize the important factors in providing adequate care and support to the DSD population.

Attendance Verification Code: _____

D08: Sharing is Caring: Extending Shared Decision Making Principles into Genetic Counseling Practice

1.50 Contact Hours

Megan Cho, ScM, National Human Genome Research Institute; Claire Davis, MS, CGC, Sarah Lawrence College

- Summarize three main components of a succinct, evidence-based model of shared decision making: choice talk, option talk and decision talk.
- Examine personal genetic counseling practice for application of shared decision making components.
- Practice applying the component of shared decision making currently least represented in one's area of practice.

Attendance Verification Code: _____

D09: The Science of Surveys: Foundations of Survey Design and Implementation to Improve Genetic Counselor Research and Clinical Practice

1.50 Contact Hours

Kurt Christensen, MPH, PhD, Brigham and Women's Hospital, Harvard Medical School; Scott D. Crawford, MA, SoundRocket; Heather Zierhut, PhD, MS, University of Minnesota

Moderator: Julia Wynn, MS, MS, CGC

- Examine the foundations of survey development and design.
- Identify validated survey measures for use in genetic counseling research and clinical care.
- Design survey questions and measures that could be utilized in clinical care or answer genetic counseling research questions.
- Compare survey implementation methods using successful and unsuccessful examples from previous genetic counseling research studies.

Attendance Verification Code: _____

Ambry Genetics®
A Konica Minolta Company

Because close enough isn't good enough when it comes to guiding patient care.

Committed to variant detection so you can make trusted healthcare decisions with your patients.

Scientific Excellence and Quality Genetic Testing Since 1999

Variant Classification
Genetic experts classify every variant to ensure clear results

Secondary Confirmation
Going above and beyond with published metrics in our confirmation testing

Gene Classification
We select our genes based on proven disease-causing relationships

ATG Lab
Only lab to provide complimentary RNA studies

Learn more about our dedication to improving patient care.
ambrygen.com/ourquality

Platform Presentations

FRIDAY, NOVEMBER 16 | 10:45 am – 12:00 pm | 1.25 CONTACT HOURS

	C06 Cancer Guidelines and Risk Assessment *Room C112* ■ Evaluate the effectiveness of recommendations and guidelines for genetic testing and screening. ■ Describe factors influencing the decision making process for individuals at risk for cancer.	**C07 Counseling/ Psychosocial** *Room C202-C204* ■ Develop frameworks for expanding and evaluating genetic counselor practice. ■ Identify novel ways of addressing patients' clinical/emotional needs.	**C08 Diversity and Access** *Georgia Ballroom* ■ Explore experiences and perspectives of patients from varying backgrounds. ■ Examine issues related to equitable access to genetic counseling services. Amicus Therapeutics	**C09 Variant Interpretation and Diagnostic Utility** *Room C111* ■ Examine factors underlying variant classification and calls. ■ Explore possible genotype/phenotype relationships. INVITAE	**C10 Training and Workforce** *Room C113* ■ Summarize select genetic counseling workforce issues and initiatives. ■ Examine methods and modalities for training genetic counseling students.
10:45 am – 11:00 am	Moderate Penetrance Breast Cancer Genes: Surgical Decisions and Bilateral Breast Cancer Risk *Jordan Berg*	Psychometric Properties of the Genetic Counselling Outcome Scale (GCOS): A Rasch Analysis *Presenter*	Understanding Barriers to Genetic Testing for Sickle Cell Trait: The African-American Male Perspective *Shandrea Da'chelle Foster*	Clinical Utility of Clinical Whole Genome Sequencing: A Review of Pilot Data from 88 Cases *Carolyn Brown*	Perspectives from the Trenches: An Analysis of How The Workforce is Currently Utilized to Train The Next Generation of Genetic Counselors *Ashley Barnes*
11:00 am – 11:15 am	Identifying Individuals with Mutations Prior to Cancer Diagnoses Using NCCN Criteria: Successful or Not? *Brian Reys*	Effect of Providing Education about Carrier Results via Web versus Genetic Counselor on the Subsequent Therapeutic Relationship *Lori A. Hamby Erby*	Meeting The Needs of Low Health Literacy Patients in The Era of Precision Medicine: A Pilot Intervention to Improve Patient-provider Communication in Cancer Genetic Counseling *Galen Joseph*	Incorporation of Genetic Testing for Familial Hypercholesterolemia Doubles Diagnosis Rate *Emily Brown*	Statewide Assessment of The Utah Genetic Counseling Clinical Workforce *Karin M. Dent*
11:15 am – 11:30 am	Triple Negative Breast Cancer: An Indication for Testing Beyond *BRCA 1/BRCA 2* *Kristen J. Vogel Postula*	Adult-onset Neurologic Disease Risks in Carriers of Recessive Conditions: Current Knowledge, Practices and Attitudes of Genetic Counselors Providing Carrier Screening *Tara A. Jones*	Attitudes and Beliefs of the Amish and Mennonite Communities towards Medical Photography in the Context of Facial Dysmorphology Novel Analysis *Jillian Lineburg*	In a Class All by Itself: The Importance of Reclassifying Genes and Variants to Better Guide Patient Care *Zoe Powis*	Standardized Patients: Enhancing Genetic Counseling Graduate Training *Lisa Jay Kessler*
11:30 am – 11:45 am	Discussion and Moderation *Moderator: Scott Weissman*	Rare Disease Caregiving in America: What Genetic Counselors Need to Know *Erica Ramos*	Closing the Disparity Gap: Alternative Service Delivery Models as an Opportunity to Increase Access to Genetic Testing in Underrepresented Groups *Lauren Ryan*	Outcomes of 94 Patient-driven Family Studies for Reclassification of Unselected Variants of Uncertain Significance *Ginger Jade Tsai*	Exploring the Developmental Process of Genetic Counseling Supervisors *Caitlin Reid*
11:45 am – 12:00 pm		Preimplantation Genetic Diagnosis in Inherited Heart Diseases: A Qualitative Study *Laura Yeates*	Geometric Inclusivity: An Assessment of Current Practices in Pedigree Nomenclature for Patients Identifying as Transgender and Gender Nonconforming *Liz Sheehan*	Variant Interpretation is a Wide-spread and Valuable Practice amongst Clinical Genetic Counselors across Multiple Specialties *Karen Wain*	The Current Landscape of Genetic Counseling Licensure in the United States *Natalie Vena*

SATURDAY, NOVEMBER 17, 12:00 pm – 1:15 pm | 1.25 CONTACT HOURS

	D10 Service Delivery *Room C202-C204* ■ Explore novel approaches to improve genetic counseling. ■ Examine tools and modalities to supplement practice.	D11 Incidental and Unexpected Findings *Room C111* ■ Explore the impact of genetic test results and implications of incidental findings. ■ Examine unexpected results in genetic testing.	D12 Neuromuscular/ Psychiatric *Room C113* ■ Examine the role of genetic variance in psychiatric risk assessment. ■ Exploring various aspects of patient experiences with neuromuscular diseases, diagnoses, testing and screening.	D13 ELSI *Room C208-C210* ■ Evaluate professional ethics in genetic counseling practice. ■ Illustrate ethical implications across the genetic counseling process.	D14 Cancer *Room C112* ■ Differentiate factors influencing the decision making process for individuals at risk for cancer. ■ Summarize various research studies related to hereditary cancer genetics.
12:00 pm – 12:15 pm	Barriers Associated with Uptake of Genetic Counseling and Testing in a Randomized Study of Remote Genetic Services Compared to Usual Care in Community Practices without Genetic Providers *Cara Cacioppo*	Proactive Genetic Screening in a Primary Care Setting Reveals Surprising Results *Allison Janson Hazell*	*Cyp2C19* Genotype is Associated with Tolerability and Response Outcomes in Es/Citalopram-Treated Youth with Anxiety and/or Depressive Disorders *Stacey Aldrich*	Outcomes of Return of Secondary Findings among a Multi-site Study *Barbara Bowles Biesecker*	Identification of Cancer Risk During Prenatal Genetic Counseling Sessions: Evaluation of Current Practice Protocols *Jennifer Cech*
12:15 pm – 12:30 pm	Leveraging Scalable Genetic Counseling Tactics to Meet the Needs of a Statewide Genomic Screening Initiative *Kelly Moreland East*	Counseling Conundrum: Sex Discordance Identifcation following Preimplantation Genetic Testing for Aneuploidy (PGT-A) or Non-invasive Prenatal Testing (NIPT) Using Snaps-based Methodologies *Katherine L. Howard*	Open Communication of Duchenne Muscular Dystrophy Facilitates Disclosure Process by Parents to Unaffected Siblings *Laura Anne Goodell*	Ethical Implications of Laboratory-sponsored Items and Events for Genetic Counselors: An Exploratory Study *Arielle Flynn*	Information Seeking and Scanning Behaviors in Individuals Scheduled for Cancer Genetics Consultations *Sabrina Nichole DiMaso*
12:30 pm – 12:45 pm	Cost-savings and High Patient Satisfaction with Automated Disclosure of NIPT Results *Cassidi Dailey Kalejta*	Discovery of Y Chromosome SNPs on DTC Testing Leads to a 46, XY Disorder of Sexual Differentiation Diagnosis in a 32 year-old Woman *Brooke Moriarty Nightingale*	The Role of *MTHFR* C677T Variants in Postpartum Psychopathology: A Prospective Study of at-risk Women to Inform Prenatal Genetic Counseling Practice *Emily Morris*	Challenges to Informed Consent for Exome Sequencing: A Best Worst Scaling Experiment *Rachel Gore*	Patient Reported Barriers to Genetic Counseling for Hereditary Breast and Ovarian Cancer Risk *April Hermstad*
12:45 pm – 1:00 pm	Genetic Education: Patient Satisfaction with a Prenatal Video Tool *Joan B. Oliver*	A Pilot Study of CLIA-compliant Secondary Findings in Research Sequencing: Outcomes amongst Recipients of Positive and Negative Reports *Julie Chevalier Sapp*	Survey Validation for Screening of Hypermobile Ehlers-Danlos Syndrome *Megan Quinlan*	Adolescents Share Their Views: A Qualitative Analysis of Adolescents' Preferences for Learning Genomic Sequencing Results *Josie Pervola*	Why Don't Women Respond to Risk Notification Letter Following Mammography? *Allison Schartman*
1:00 pm – 1:15 pm	A Novel Automated Service Delivery Model for Negative NIPT Results in the Era of Technology Enabled Healthcare *Cassidi Dailey Kalejta*	A Comprehensive Look at the Neurodevelopmental Outcomes and the Effects of Early Hormonal Therapy in a Large, Prenatally Diagnosed Population of Boys with 47,XXY (Klinefelter Syndrome) *Carole Samango-Sprouse*	Genetic Testing of Patients with Cerebral Palsy Reveals One-third of Cases Have a Monogenetic Cause and a Significant Recurrence Risk *Claire Teigen*	Moral Distress in Genetic Counseling *Erin Wadman*	Uveal Melanoma Prognostic Genetic Testing: An Emerging Role for Genetic Counselors *Honey Nagakura*

TEST EARLY. DIAGNOSE SOONER.

CUSTOMIZE CARE FASTER WITH NO-COST TESTS

Simply Test for MPS™

AN MPS ENZYME PANEL FOR:

- Patients exhibiting signs and/or symptoms consistent with an MPS disorder:

Sara, 27
Diagnosed with SED at age 8. Correct diagnosis of MPS IVA diagnosed at age 26.

BEHIND the SEIZURE™

A COMPREHENSIVE EPILEPSY GENE PANEL FOR:

- Children aged 2 to 4 years who experienced their first unprovoked seizure after the age of 2

Eli, 3
Diagnosed with CLN2 disease at age 2.

Consider no-cost testing for your eligible patients today

VISIT SIMPLYTESTFORMPS.COM

VISIT BEHINDTHESEIZURE.COM

©2018 BioMarin Pharmaceutical Inc. All Rights Reserved. USMPRL0039 0818

BIOMARIN®

Posters With Authors

Objectives:

- Recognize varied approaches to building an evidence base to support best practices in genetic counseling.
- Identify opportunities for the genetic counseling community to expand the reach of genetic/genomic-based care.
- Evaluate the varied settings in which genetic counseling expertise is utilized.

A09 GROUP A POSTERS
Wednesday, November 14
5:45 pm – 7:00 pm
CONTACT HOURS: 1.25

B20 GROUP B POSTERS
Thursday, November 15
6:00 pm – 7:15 pm
CONTACT HOURS: 1.25

C13 GROUP C POSTERS
Friday, November 16
1:30 pm – 2:45 pm
CONTACT HOURS: 1.25

GROUP A POSTERS

Access and Service Delivery

A-1 High Throughput Counseling: Meeting the Demand for Carrier Screening Results Disclosure and Patient Management
Aishwarya Arjunan

A-4 Health Literacy Effects on Health-related Needs of Pregnant Women and Their Caregivers
Sarah Carpenter

A-7 The Pediatric Cardiovascular Genetic Counseling Service: A Unique Convergence of Clinical Genetics and Cardiovascular Care
Samantha Freeze – Withdrawn

A-10 Barriers and Facilitators to Reaching a Diagnosis of Monogenic Diabetes from the Patients' Perspective: A Qualitative Study
Yue Guan

A-13 The Current State of Genetic Counseling Assistants
Morgan Hnatiuk

A-16 Implementation of Dedicated Cascade Testing Clinic to Improve Access and Efficiency
Michelle Jacobs

A-19 Detecting Unaffected Individuals for Lynch Syndrome (DUAL): An Institutional Experience
Sayoni Lahiri

A-22 Beyond the Clinic: A Pilot Study Integrating Genetic Counseling and Mobile Health Technology
Kestutis Micke

A-25 Genetic Counseling in an Emergent Country: Disparity in Access to Genetic Cancer Risk Assessment for Breast Cancer within the Mexican Population
Guillermo Pacheco-Cuellar

A-28 On Second Thought…Updates to Personal and Family History Using an Interactive Online Tool
Lauren Ryan

A-31 A Need for Genetic Screening/Counseling Referrals in Breast, Ovarian, Colorectal and Endometrial Cancer
Kathryn Ann Mraz

Adult

A-34 The Complexity of Genetic Counseling for Pulmonary Fibrosis
Nikkola Carmichael

A-37 Overlapping Phenotypes of Spondylometaphyseal Dysplasia-Kozlowski Type and Charcot-Marie-Tooth Disease Type 2C Secondary to a *TRPV4* Pathogenic Variant
Eden Faye

A-40 Pain and Fatigue Associated with Generalized Joint Hypermobility in Gaucher Disease
Farrah Mahan

A-43 The Clinical Utility of Genetics Services for the Ehlers Danlos Syndrome, Hypermobility Type, Population
Carolyn Serbinski

Cancer

A-46 Cancer Risk Education and Wellness (CREW) Tool: Development and Analysis
Zoe Bogus

A-49 Is Less Really More? The Influence of Demographic Factors on Multi-gene Panel Testing Choice for Inherited Breast Cancer Syndromes
Katherine Clayback

A-52 Genetic Testing Alters Care for Von Hippel-Lindau Syndrome Phenocopy
Morgan Depas

Posters With Authors (continued)

A-55 What You Find When You Go Looking: A Unique *CTNNA1* Variant in an Early Onset Diffuse Gastric Cancer
Dana Farengo Clark

A-58 Acute Cutaneous Toxicity in Women with Breast Cancer and Heterozygous Mutations in Breast Cancer Genes
Amber Gemmell

A-61 An Unexpected Pathogenic *SDHC* Variant Detected by Germline Cancer Panel Testing
Carolyn Haskins

A-64 The Clinical Utility of Genetic Testing for Moderate Penetrant Breast Cancer Genes: A Systematic Review of Cases
Christine Keywan

A-67 Ovarian Endometrioid Adenocarcinoma with Focal Yolk Sac Differentiation in a Pre-menopausal Patient Leading to Diagnosis of Lynch Syndrome
Brooke Levin

A-70 Paired Germline Testing and Somatic Tumor Sequencing for Lynch Syndrome: The Clinical Challenges of Uncertain Results
Kimberly Matthijssen

A-76 When Do Clinicians Cast a Wider Net? Utilization of the Largest Comprehensive Cancer Panel at One Commercial Laboratory
Sara Wienke

A-79 From Uncertainty to Pathogenicity: Demonstrating the Significance of a *TP53* In-frame Deletion
Emily Quinn

A-82 An Analysis of Information Captured in Genetic Counseling Cancer Pedigrees of Hispanic-American Patients
Katherine Sanders

A-85 Identification of Women at-risk for Lynch Syndrome in a Mammography Population
Allison Schartman

A-88 Extracolonic Cancer Risks in Monoallelic and Biallelic *MUTYH* Carriers: A Multicenter Exploratory Study
Valerie Slegesky

A-91 Evaluation of Breast Cancer Surveillance Guidelines for *CHEK2* Mutation Carriers
Elise Watson

A-94 Polygenic Breast Cancer Risk: A Prospective Study of Uptake and Outcomes among Women at High-risk for Breast Cancer
Tatiane Yanes

A-97 Compliance among High-risk Patients Identified through Hereditary Cancer Population Screening
John Zimmerman

Cardiology

A-100 *BRCA*-related Phenocopy in Arrhythmogenic Cardiomyopathy
Robyn Hylind

A-103 Expanding the Clinical Phenotype for Marfan Syndrome
Rebecca Miller

A-106 Beyond *FBN1*: Multigene Panel Testing for Marfan Syndrome
Zoe Powis

A-109 Titin-related Cardiomyopathy in a Pediatric Population: A Case Series
Amy Shikany

A-112 Genetic Mutation and Copy Number Variation in Pulmonary Arterial Hypertension Associated with Congenital Heart Disease
Xuan Zheng

Counseling/Psychosocial Issues

A-115 Effects of Communication Complexity on Analogue Clients in a Video Cancer Genetic Counseling Session
Emily Bonkowski

A-118 Factors Influencing Uptake of Bilateral Prophylactic Mastectomy Between the ages of 20 and 30 years in Unaffected Women with a *BRCA1/BRCA2* Mutation
Meera Clytone

A-121 Challenges in Genetic Counseling for Biallelic Expansions in Adult Onset Disorders
Kaylee Faulkner Naczi

A-124 Skillfulness is in the Eye of the Beholder: An Investigation of Genetic Counselors' and Proxy Patients' Perceptions of Genetic Counselor Self-disclosure and Non-disclosure
Veronica Greve

A-127 Family Planning Decisions after a Child's Diagnosis of Rett Syndrome: A Pilot Study
Erin Huggins

A-130 Disclosure of Genetic Information in Families Affected by Hereditary Ataxia
Katherine Lincoln

A-133 Journey of Fathers following Their Child's Fragile X Diagnosis: Support Seeking Behaviors of Fathers
Aman Mann

A-136 Lack of Referral and Evaluation Compounds Emotional Distress in Three Generational Family with Tuberous Sclerosis Complex
Jennifer Propst

A-139 Complexities of Preconception Decision Making in Hereditary Retinoblastoma
Jaclyn Schienda

A-142 Spiritual Care in Cancer Genetic Counseling: Patient Perceptions of Methods
Christopher Spencer

A-145 A Case Report of the Prenatal Diagnostic Odyssey Resulting from Abnormal cfDNA Screening Results
Abigail Weinberg

Education

A-148 Self-reported Skills of New Leaders in Genetic Counseling Training Programs
Karin Dent

A-151 Is Current Fragile X Syndrome Counseling Enough? Expanding the Clinical Phenotype of Fragile X in Premutation and Intermediate Allele Carriers
Zahra Girnary

A-154 Genetic Counselors' Attitudes toward Continuing Education Options
Kelsey Johnson

A-157 Assessing the Disease Specific Knowledge Gaps in Patients and Caregivers Living with Lysosomal Storage Diseases
Georgia Loucopoulos

A-160 Examining the Relationship between Genetic Counseling Self-efficacy and Clinical Training
Elizabeth Owens-Thomas

A-163 Evaluating Patient Satisfaction with Genetic Counseling Sessions: What is the Impact of Genetic Counseling Trainees?
Alison Robzen

Ethical, Legal and Social Issues

A-166 Healthy Genomic Sequencing: What Airmen Want to Know? Findings from the MilSeq Project
Carrie Blout

A-169 Genetic Information in the Pediatric Solid Organ Transplant Setting: How Knowledge of Future Genetic Risk Impacts Listing Decisions
Madeline Graf



Posters With Authors (continued)

A-172 Prenatal Genetic Counselors' Perceptions of the Impact of Abortion Legislation on Counseling and Access in the United States
Susheela Jayaraman

A-175 When Did Genetic Counseling Become Privacy Counseling?! Introducing the Future of Privacy Forum's "Privacy Principles for Genetic Data"
Misha Rashkin

Genetic/Genomic Testing

A-178 Incidental Somatic and Germline *RET* Mutation in a Patient with Merkel Cell Carcinoma and a Complex Oncology History: A Case Study
Dina Alaeddin

A-181 Pediatric Perspective: Genome Sequencing for Newborn Screening
Emily Anderson

A-184 Parental Expectations and Perceived Utility of Pharmacogenomic Testing for Therapeutic Optimization of Neuro-psychiatric Medications
Courtney Berrios

A-187 What We Learn from the Unknown – VUS Rates by Ethnicity and Gene
Wanchun Cheng

A-190 Elective Genome Sequencing Reveals Homozygous *RAPSN N88K* Founder Mutation in an Asymptomatic 59 year-old with an Affected Brother, Expanding Clinical Variability and Presenting Counseling Challenges
Callie Diamonstein

A-193 A Case for the Continued Importance of Cytogenetics in Rare Diagnosis of Triploid/Diploid Mixoploidy
Leslie Durham

A-196 Parent Experience with Genetic Testing for Pediatric Epileptic Encephalopathy: What Can We Do Better?
Rhonda Feinbaum

A-199 Withdrawn

A-202 Genetic Counselors' Perspectives on Expanded Carrier Screening Use in Assisted Reproductive Technologies
Ellen Johnson

A-205 What's in a VUS Rate? Simulated VUS Rate Calculations for Hereditary Cancer Genes Using Population Frequency Data and ClinVar Submissions
Kristjan Kaseniit

A-208 Experiences of Whole Exome Sequencing in a Pediatric Intensive Care Unit
Natalie Lippa

A-211 The Use of Pheno Analysis to Reclassify Variants in Moderate Penetrance Genes (*CHEK2, ATM, BARD1*) with Analysis of the Effects of Reported Cancer History Errors
Jamie Wilmott

A-214 Genetic Counselors' Perceptions and Experiences of Counseling and Testing for Low Penetrance Alleles
Kaylin O'Brien

A-217 Genome-wide cfDNA Testing: Clinical Laboratory Experience Screening for Select Microdeletions
Kimberly Fanelli

A-220 A Retrospective Analysis of Clinical Whole Genome Sequencing Results After Non-diagnostic Microarray or Whole Exome Sequencing
Alicia Scocchia

A-223 Primary Care Physicians' Perspectives on Positive Newborn Screens for Cystic Fibrosis: A Statewide Survey
Jessica Tarnowski

A-226 Genetic Testing Preferences and Intentions in Patients with Clinically Diagnosed Familial Hypercholesterolemia
Hannah Wand

A-229 Patients' Reactions and Follow-up Testing Decisions Related to Tay-Sachs (*HEXA*) Variant of Uncertain Significance Results
Tiffany Yip

Other

A-232 Development of a Patient-reported Outcome Measure in Mitochondrial Myopathy: Patient Perspective
Natalie Burrill

A-235 A Survey of Eating Attitudes and Behaviors in Adolescents and Adults with Phenylalanine Hydroxylase Deficiency
Sharon Luu

Pediatrics

A-238 The Clinical Journey of Patients with Riboflavin Transporter Deficiency Type 2
Fatima Amir

A-241 Variable Presentations in Three Children with PURA Syndrome
Campbell Brasington

A-244 Clinical Diagnosis of Russell-Silver Syndrome Resulting from a Beckwith-Wiedemann Syndrome Genotype
Ashleigh Hansen

A-247 Experience of Youth and Families with Special Healthcare Needs in Transition to Adult Healthcare Services
Kelly Kemak

A-250 Parental Experience with Whole Exome Sequencing Reanalysis and its Impact on the Diagnostic Odyssey
Nicole Lucas

A-253 Perceptions of Transition: Readiness and Needs Assessment in Adolescents with Neurofibromatosis Type 1
Brianna Murray

A-256 Chromosome 3p Inverted Duplication with Terminal Deletion: Second Postnatal Report with Additional Clinical Features
Jacquelyn Riley

A-259 Investigating the Role of Intragenic *YWHAE* Copy Number Variations in Neurodevelopmental Disorders
Abby Stevens

A-262 Beyond *PKHD1*: Reconsidering Genetic Testing for Neonatal Polycystic Kidney Disease
Grace VanNoy

Pre- and Perinatal

A-265 Associations between Ultrasound Soft Markers and Copy Number Variants
Lindsay Bailey

A-268 Utilization of cffDNA Testing in a Publicly Funded Contingent Prenatal Screening Model
Kara Bellai Dussault

A-271 Non-invasive Prenatal Testing in Australia: A Qualitative Exploration of Women's Experiences in Private and Public Settings
Eliza Courtney

A-274 Pregnancy Outcome Information after Receiving an "Aneuploidy Suspected" Screen Result via Non-invasive Prenatal Screening
Jordan D. Dix

A-277 Cell-free DNA Testing at Nine Weeks: A Clinical Laboratory Experience
Kimberly Fanelli

Now Available

Galafold™
(migalastat) 123 mg capsule

Sign up for more information at **Galafold.com**

IMPORTANT SAFETY INFORMATION

What is Galafold?

Galafold is a prescription medicine used to treat adults with Fabry disease who have a certain genetic change (variant) in an enzyme called alpha-galactosidase A (*GLA*) that is responsive (amenable) to Galafold.

It is not known if Galafold is safe and effective in children.

Before taking Galafold, tell your healthcare provider about all of your medical conditions, including if you:

- have kidney problems.
- are pregnant or plan to become pregnant. It is not known if Galafold will harm your unborn baby.
- are breastfeeding or plan to breastfeed. Galafold may pass into breast milk. Talk to your healthcare provider about the best way to feed your baby if you take Galafold.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

What are the possible side effects of Galafold?

The most common side effects of Galafold were headache, stuffy or runny nose and sore throat, urinary tract infection, nausea, and fever.

These are not all the possible side effects of Galafold. Call your healthcare provider for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. You may also report side effects to Amicus Therapeutics at 1-877-4AMICUS.

Please see accompanying Full Prescribing Information, including Patient Information and Instructions for Use.

Amicus Therapeutics®

Galafold is a trademark of Amicus Therapeutics, Inc.
© 2018 Amicus Therapeutics, Inc. PP-GA-US-0011-0718

Posters With Authors (continued)

A-280 Continuing Genetics Education May Increase OB/GYN Referrals to Prenatal Genetic Counseling
Devin Fendlay

A-283 Value of Pan-ethnic Expanded Carrier Screening in the Evaluation of Fetal Structural Anomalies
Jessica Giordano

A-286 Serendipitous Detection of Maternal Tetrasomy 9p as a Result of Prenatal Cell-free DNA Screening
Cheryl Harper

A-289 Giant Omphalocele: What is the Genetic Association?
Mary-Kayt Jones

A-292 A Case of Extremely Elevated Maternal Serum Alpha-Fetoprotein (MSAFP)
Karen Marchand

A-295 Do Years of Experience as a Genetic Counselor Affect Likelihood to Pursue Carrier Screening?
John Quinlan

A-298 How Do Patients Attending Prenatal Genetic Counseling Sessions Feel about and Respond to Being Asked about Personal or Family History of Mental Illness?
Sarah Nimrichter

A-301 Exploring Counseling Trends with Cell-free DNA (cfDNA) in Genetic Counseling
Miranda Ruben

A-304 Follow Your Nose: The Impact of Repeat Nasal Bone Evaluation on Down Syndrome Risk Assessment by First Trimester Screening
Katelynn Sagaser

A-307 Exploring Women's Perceived Support for Abortion Due to Fetal Anomaly: Stigma in the Medical Community
Jordan Snajczuk

A-310 Prenatal Genetic Counseling for Marijuana or Opioid Use During Pregnancy
Naomi Wagner

A-313 Approach to Encourage Expectant Couples in Japan to Understand about Living with Children with Down Syndrome
Motoko Watanabe

Professional Issues

A-316 Identifying Genetic Counselor Roles in Facilitating Cascade Screening
Sarah Austin

A-319 Analysis of the Genetic Counseling Job Market – The Future is Bright
Kaitlyn Burns

A-322 Participant Satisfaction with a Prospective Genetic Counselor Volunteer and Professional Development Program
Julia Platt

A-325 Perceived Role of Clinical Experience in Industry Positions: A Qualitative Study with Industry Genetic Counselors
Janine Kakishita

A-328 Genetic Counselors' Implementation of Self-care and Self-awareness
Lauren Loffredo

A-331 Genetic Counselor Interactions with Genetic Testing Industry: Prevalence and Perceptions
Chandler L. Stimach

A-334 Bridging the Gap: The Role of Genetic Counselors in Cord Blood Banking and Stem Cell Therapy
Jessica Zoladz

Psychiatry/Neurology

A-337 Withdrawn

A-340 The Relationship between Age-of-onset and the Behavioral Phenotypic Manifestations in Huntington's Disease
Megha Ranganathan

A-343 Three Generations of *SCN8A*-related Early-onset Epilepsy Patients Presenting with Milder Phenotype
Carol Symmons

Public Health

A-346 Accuracy and Performance of a Digital Identification Tool for Hereditary Cancer in a Largely Unaffected Population
Leslie Bucheit

A-349 Newborn Screens From Start to Finish: One Institutions 10-year Experience of Abnormal Newborn Screens for Very Long Chain Acyl-CoA Dehydrogenase Deficiency
Melanie Goodman

Research Issues

A-352 A Prospective Survey of Aortic Disease Biorepository Participants' Preferences for Method of Return of Research Genetic Results
Jamie Love-Nichols

Utilization Management

A-355 Withdrawn

A-358 Expansion of a Laboratory Utilization Management Program: The Importance of Clinical Genetic Counselors Practicing with Their LUM "Hat" On
Shelly Weiss

GROUP B POSTERS

Access & Service Delivery

B-2 Billing and Credentialing in the Lone Star State: A Survey of Genetic Counselors' Practices Sans Licensure
Katie Bergstrom

B-5 EPIC Fail! Effect of Electronic Health Record Transition on First Trimester Screening Results Reporting, an Illustration of the Role of Genetic Counselors in Ensuring Patient Notification
Martha Shaw Dudek

B-8 Experience of Telehealth Cancer Genetics Practice in a Large Community Healthcare System
Mariah Gleason

B-11 Identifying Genetics Referrals within a Radiology Practice in a Community Based Hospital Setting
Julie Handy

B-14 "A Positive Light for Our Community": Hmong Reactions to Receipt of Individual and Community Pharmacogenetic Research Results
Katherine Holzer

B-17 A Survey of ALS Clinician Genetic Testing Practices Identified Lack of Consensus on the Offer of Testing and Divergent Views Towards Testing as Compared to ALS Patients
Holly Klepek

B-20 Looking Deeper: Experiences of a Newly Founded Multidisciplinary Differences of Sexual Development and Endogenetics Clinic at Children's Hospital of Philadelphia (CHOP)
Jacqueline Leonard

B-23 Development of the First Dedicated On-call Cardiovascular Genetic Counseling Service
Tia Moscarello

B-26 Improving Timely Access to Genetic Counseling for Oncology Patients Through an Integrated Telehealth Genetic Counseling Service
Kiley Johnson

B-29 Getting Lean: Improving Efficiency in Genetics Clinics
Christine Spaeth

B-32 A Survey of Genetic Counselors' Current Methods of Implementing Telegenetic Services
Brenda Zuniga

Adult

B-35 Beyond the Numbers: Age and Penetrance in Huntington Disease
Tanya Eble

B-38 Assessing the Effects of Renin Angiotensin System Drugs on Lung Function in Patients with Cystic Fibrosis
Stephanie Gerber

B-41 Healthcare Transitions for People with Thalassemia
Lauren Morse

Cancer

B-44 Characteristics of Patients with a Primary Brain Tumor Undergoing Panel Genetic Testing
Sarah Azam

B-47 Increased Incidental Cancer Risk Identified in Prenatal Three-generation Pedigrees Obtained in 2016 as Compared to 2010
Jennifer Cech

B-50 Double Take! Mosaic Li Fraumeni Syndrome in Monozygotic Twins
Victoria Costello

B-53 Integrating Genetic Counseling and Testing in the Pediatric Oncology Setting: Parental Attitudes and Influencing Factors
Lauren Desrosiers

B-56 Gastrectomy Decisions in Asymptomatic *CDH1*+ Patients Over Age 50: Implications for Ongoing Interdisciplinary Care with Genetic Counseling
Grace-Ann Fasaye

B-59 Managing the Unexpected: Genetic Counseling of Complex Family Histories of Colon and Endometrial Cancer
Amber Gemmel

B-62 Evidence for the Continuation of Surveillance Practices for *SDHX*-mutation Carriers After the Age of 50
Rachel Holman

B-65 Findings Beyond *BRCA1/2* Impact Management of Hereditary Breast Cancer Families
Lindsay Kipnis

B-68 A Novel *GATA1* Mutation in a Female with Myelofibrosis
Shao-Tzu Li

B-71 Hereditary Paragangliomas and Pheochromocytomas: An Update in Genetic Testing Strategies
Caitlin Mauer

B-74 Attitudes toward Updated Genetic Testing among Patients with Unexplained Mismatch Repair Deficiency
Jessica Omark

B-77 Universal Screening of Colorectal Tumors for Lynch Syndrome: A Survey of Patient Experiences and Opinions
Alexander Petterson

B-80 Exploring Family Communication Regarding Cancer Genetic Testing for the Most Informative Results
Maija Rannikko

Posters With Authors (continued)

B-83 Evaluation and Feedback Implementation for Iterative Development of a Relational Cancer Knowledgebase with Improved Utility for Clinical, Research and Educational Purposes
Kunal Sanghavi

B-86 Identification of a *CHEK2* Mutation in a Transgender Female with DCIS: A Case Report
Amanda Schott

B-89 Tumor Profiling and Hereditary Risk Identification: The Continued Role of a Genetic Counselor
Samantha Stachowiak

B-92 Expected versus Observed Phenotype-genotype Associations with APC Pathogenic Variants
Erica M. Webb

B-95 Parental Attitudes regarding the Need for Genetic Services in a Pediatric Brain Tumor Survivorship Population
Alice Zalan

Cardiology

B-98 Variants at the p.Arg453 Locus in *MYH7* Associated with Severe, Pediatric Hypertrophic Cardiomyopathy
Emily Brown

B-101 Arterial Tortuosity Syndrome in a Chinese Pediatric Patient: A Case Report
Xuan Zheng

B-104 Penetrance of HCM in at-risk Children and Young Adults is Related to Gene Mutation Status
Erin Miller

B-107 Cardiovascular Genetics: Getting a "Pulse" on How Cardiologists Assess and Act on Cardiogenetic Findings that May Lead to Sudden Cardiac Death
Anna Danielle Levy

B-110 Stepping in and out of Uncertainty: Views of Receiving a Genetic Variant Reclassification in Patients with Inherited Cardiac Disease
Eugene Wong

Counseling/Psychosocial Issues

B-113 Ehlers Danlos Syndrome: An Emerging Adulthood Perspective
Katie Bealka

B-116 Recurrence Numbers in Genetic Counseling: Exploring Uptake, Perception and Impact on Patient Outcomes
Kennedy Borle

B-119 More Than Three Founder Mutations for Ashkenazi Jewish Ancestry in a Hereditary Cancer Clinic
Devin Cox

B-122 An Exploration of Factors Influencing Patient Outcomes of Psychiatric Genetic Counseling
Sarah Gerrard

B-125 Genetic Counselors' Experiences with Incidental Findings of Misattributed Paternity
Janey Youngblom

B-128 Potential Methods to Strengthen the Counselor-patient Alliance in a Genetic Counseling Session: Nonconscious Priming and Empathetic Phrasing
Jessica Isaacs

B-131 Evaluating the Utility of an Options for Pregnancy Termination (OPT) Decision Aid: Perspective of Genetic Counselors
Vivian B. Ling

B-134 Depression Screening in a High Volume Cancer Genetics Program
Jacqueline Mersch

B-137 Exploring Empathy in Genetic Counseling Students and New Genetic Counselors
Jonica Richards

B-140 "Just a Little Bit Different": The Experiences of Emerging Adults at-risk for and Living with Genetic Conditions
Anna Shelley

B-143 Disability Identity and Attitudes towards Prenatal Testing in the Osteogenesis Imperfecta Community
Rachel Sullivan – Withdrawn

B-146 Infertility and Familial Adenomatous Polyposis: A Topic Genetic Counselors Should Discuss?
Heather Willems

Education

B-149 What Walls? Demystifying the Role of Race/Ethnicity in Genetic Counseling Supervisory Relationships
Cheyenne Dewey

B-152 Genetic Counselors in the Middle School Classroom: A Pilot Study to Raise Awareness of and Interest in the Field
Allison Hutchinson

B-155 OB/GYN Residents' Training, Attitudes and Comfort Level regarding Genetics
Anastasia Kathrens-Gallardo

B-158 MedGen: Your Access to Medical Genetics Information
Adriana Malheiro

B-161 An Assessment of Pediatric Cancer Genetic Counseling Training in Genetic Counseling Programs
Eleanor Peacock

B-164 Websites on Inherited Thrombophilia and Pregnancy Risk Lack Adequate Quality, Content and Readability to Facilitate Health Decision Making
Julie Solimine

Ethical, Legal and Social Issues

B-167 Implementation of Conditional Free Predictive Testing for Cancer Predisposition: The Impact on Uptake for Syndromes with Pediatric Onset
Eliza Courtney

B-170 Attitudes of People with Inherited Retinal Conditions toward Gene Editing Technology
Lily Hoffman-Andrews

B-173 Disclosure of Reclassified VUS Results of Deceased Patients to Family Members: Current Practices
Seth Lascurain

B-176 Patient Experience with the Consent Process of Preimplantation Genetic Diagnosis (PGD) and Preimplantation Genetic Screening (PGS)
Kimberly Skellington

Genetic/Genomic Testing

B-179 The Role of Familial Cancer Risk on Predictors of Genetic Testing and Counseling for Hereditary Breast and Ovarian Cancer
Caitlin Allen

B-182 Perspectives of Pediatric Providers Regarding Clinical Use of Pharmacogenetics
Kayleigh Avello

B-185 Complex Chromosomal Rearrangements Revealed through Genome-wide cfDNA: 40,000 Samples
Theresa Boomer, Sidra Boshes

DECIPHERING THE TUMOR GENOME

CE CERTIFIED

Exploring Molecular & Clinical Advances in the DNA Damage Response Pathway

Justine Cooper Pickarski, MS, CGC
University of Kentucky
Markey Cancer Center
Lexington, Kentucky

Nadine M. Tung, MD
Harvard Medical School
Boston, Massachusetts

Presented by Creative Educational Concepts, Inc.

cec oncology

Supported through an independent educational grant from AstraZeneca.

TARGET AUDIENCE

Genetic counselors, medical and clinical geneticists, laboratory researchers, nurses, physicians, physician assistants, and all medical practitioners who are involved in the diagnosis, management, and genetic counseling of patients who have or are at risk for DDR-mutated cancers.

OBJECTIVES

Upon completion of this activity, participants will be able to:

1. Outline the role of the DNA damage response (DDR) pathway in tumor suppression and describe how mutations in DDR genes lead to tumor proliferation.
2. Explore recent advances in the discovery of actionable mutations in DDR (e.g., *BRCA1/2*) and the developments in precision medicine targeting these mutations, including poly (ADP-ribose) polymerase (PARP) inhibitors.
3. Assess current guideline recommendations for genetic testing and counseling in patients with possible or known pathogenic DNA damage response mutations.
4. Using a case-based approach, evaluate challenging questions encountered in the genetic testing and counseling of *BRCA1/2* and other DDR mutations, and discuss the evolving role of the genetic counselor in the interprofessional oncology care team.

ACCREDITATION

Up to 0.1 CEUs or 1 Category 1 contact hours of NSGC credit, 1.0 *AMA PRA Category I Credits*™, 1.0 Contact Hour for Nurses, and 1.0 P.A.C.E credits.

To complete the CE activity, visit

ceconcepts.com/activity/471

Posters With Authors (continued)

B-188 Primary Findings from Elective Whole Genome Sequencing in an Ostensibly Healthy Population
Meagan Cochran

B-191 Rapid Exome Identified Dual Diagnoses, Congenital Myasthenic Syndrome and Double-dominant MYBPC3-related Neonatal Cardiac Disease, in Critically Ill Neonate, Allowing for Heart Transplant
Callie Diamonstein

B-194 Unexpected Findings from Clinical Whole Exome Sequencing for a Diagnostic Odyssey Patient: Results Suggestive of Leukemia
Marissa Ellingson

B-197 Information and Support Resources for Whole Exome Sequencing
Kathryn Gunther

B-200 Comprehensive Analysis of the ACMG59 Genes in Parental Samples Submitted for Exome Evaluation Yields a High Positive Rate
Eden Haverfield

B-203 Clinical Validity of Expanded Carrier Screening: High Concordance of Inter-lab Variant Classifications
Kristjan Kaseniit

B-206 Pathogenic *RET* Variant Identified as Secondary Result in Unaffected Parent via Trio Whole Genome Sequencing for Developmental Delay: Clinical, Familial and Psychosocial Implications
Whitley Kelley

B-209 Diagnostic Utility, Impact on Patient Management, and Outcomes of Clinical Exome Sequencing: A Survey of Ordering Clinicians
Kristy McWalter – Withdrawn

B-212 Detection of Copy-number Variants in Expanded Carrier Screening Maximizes Identification of Cystic Fibrosis Carriers
Dale Muzzey

B-215 Genetic Counselors' Perception of Uncertainty in Pretest Counseling for Genomic Testing
Jessica Park

B-218 Building a Cohort From an "n of 1": The Story of *GNB1*
Anya Revah-Politi

B-221 Impact of Functional Evaluation on Reclassifying Variants of Uncertain Significance in *KCNQ1*
Nicolette Sookar – Withdrawn

B-224 Assessing a New Genetic Counseling Referral Source: Tumor Genomic Profiling
Whitney Espinel

B-227 Preimplantation Genetic Diagnosis following Whole Exome (WES) or Whole Genome Sequencing (WGS)
Nina Wemmer

B-230 The Role of Cardiovascular, Psychiatric and Pain Pharmacogenetics in Predicting Disease Risk: A Systematic Review of Conditions Associated with Genes Commonly Tested for on Pharmacogenetic Panels
Rachel Brite Saunders

Other

B-233 Diamond Blackfan Anemia Due to a Terminal 3q Microdeletion Involving the Entire *RPL35A* Gene
Rachelle Dinchong

B-236 Our Experience in Ophthalmology Genetics Clinic
Dayna Morel Swols

Pediatrics

B-239 Newborn Screening for X-linked Adrenoleukodystrophy: A Year of Experience from a Genetic Counseling Perspective
Jessica Barry

B-242 The Relationship Between 47XXY (Klinefelter Syndrome), Autism Spectrum Traits (AST), and Early Hormonal Therapy, EHT
Selena Chea

B-245 c.103+56_34 Dup Allele in Hunter Disease May Be a Pseudodeficiency Variant: From Genetic Testing and Genetic Counseling of Maternal Families Members
You-Hsin Huang

B-248 *NDE1*-Related Disorder: A Case Report
Amy Kenney

B-251 Genotype-phenotype Correlation: An Atypical Case of Wolf-Hirschhorn with a Typical 4p Deletion
Kari Magnussen

B-254 De Novo Heterozygous *RAB3GAP1* Variant: An Exploration of a Mild Warburg Micro Syndrome Case
Hillary Porter

B-257 Novel Mutations and Clinical Features in Two Cases of WAC-related Intellectual Disability Diagnosed through Whole Exome Sequencing
Chelsea Roadhouse

B-260 Caregiver Perceptions and Quality of Life in Adolescents with Duchenne Muscular Dystrophy
Julia Stone

B-263 Assessing Family Perceptions of Diagnostic Terminology for Disorders of Sex Development (DSDs)
Stephanie Wiryaman

Pre- and Perinatal

B-266 Assessing Fertility Concerns and Reproductive Health Knowledge in Adult Males with Cystic Fibrosis
Eileen Barr

B-269 Going Against the Guidelines: Patient Decisions following Preimplantation Genetic Testing
Jillian Carroll

B-272 Genetic Counseling for Carrier Screening and Prenatal Diagnosis Involving a Tay-Sachs Disease Variant of Uncertain Significance and Possible Pseudodeficiency Allele in the East Asian Population
Jordan D. Dix

B-275 Public Interest in Carrier Screening in the Brazilian Population
Marina Dutra-Clarke

B-278 Third Trimester Cell-free DNA: A Clinical Laboratory Experience
Kimberly Fanelli

B-281 Current Genetic Counseling Practice Following Positive Non-invasive Prenatal Testing for Sex Chromosome Abnormalities
Lauren Fleddermann

B-284 Factors Predicting Prenatal Genetic Counselors Offering the Option of Adoption During Counseling Sessions
Rachel Goldberg

B-287 The Patient Perspective of the Informed Consent Process for Non-invasive Prenatal Screening
Megan Horn

B-290 An Exploration of the Involvement of Genetic Counselors in the Delivery of Aneuploidy Screening and Testing
Qian (Lorraine) Lei

B-293 Factors Influencing Decision Making about Prenatal Screening and Testing in Parents of Children with Down Syndrome
Cassidy Measner

B-296 Prenatal Microarray Detection of VCF/DiGeorge Syndrome: Impact of Ascertainment and the Importance of the Detection of a Second Microarray Abnormality
Sharon Molinari

B-299 Confirmed Trisomy 18 in a Fetus Who Was Conceived via In Vitro Fertilization with Pre-implantation Genetic Screening for Aneuploidy
Caitlin O'Brien

B-302 A Novel Prenatal Report of Post-zygotic Rescue of Partial Monosomy: Antenatal Diagnostic Work-up Unveils Homologue-templated Deletion Correction in a Structurally Normal Fetus
Katelynn Sagaser

B-305 Customizable Non-invasive Prenatal Testing for Single Gene Disorders Using Cell-free DNA
Christina Settler

B-308 Investigating Patient Misconceptions Regarding Cell-free DNA: Beyond the "Gender Test"
Stephanie Spaulding

B-311 Positive Cell-free DNA Screening for Sex Chromosome Aneuploidy: Clinical Experience and Description of Outcomes
Lauren Wallace

B-314 Factors Associated with Obtaining Results upon Repeat Cell-free DNA Testing in Samples Redrawn Due to Insufficient Fetal Fraction
Kelly Chen

Professional Issues

B-317 Genetic Counselors' Comfort and Knowledge of Cancer Risk Assessment for Transgender Patients
Tala Berro

B-320 Genetic Counselors' Perceptions of Workplace Respect and Its Influence on Professional Decision Making
Lindsay Derby

B-323 Genetic Counselors' Preparedness for Incidental Findings from Non-invasive Prenatal Testing
Paige Hazelton

B-326 An Exploration of Clinical Genetic Counselors' Interactions with Commercial Genetic Testing Laboratories
Kara Klemp

B-329 From Paper to Practice: Genetic Counseling of Consanguineous Couples
Chau Nguyen

B-332 Development of a Tool to Measure Genetic Counselor Workload Capacity in the Laboratory Setting
Elizabeth Ulm

Psychiatry/Neurology

B-335 22q and Mental Health: Development of a Resource about the Psychiatric Manifestations of 22q11.2 Deletion Syndrome
Caitlin Slomp

B-338 Compound Heterozygous Variants in *SHQ1* in Sisters with Extrapyramidal Movement Disorder
Angela Krutish

B-341 Parental Perspective Identification and Genetic Reframing of ADHD Etiology
Zachary Salvati

B-344 Exploring Genetic Counselors' Practices and Attitudes towards Patients Facing Substance Use Disorders
Allie White

Posters With Authors (continued)

Public Health

B-347 Genetic Counselors' Perspectives on Population-based Screening for Common Inherited Cancer Syndromes
Lenika De Simone

B-350 Progress of Newborn Screening Educational Materials
Amy Siemon

Research Issues

B-353 A Roadmap for Precision Medicine Research Recruitment: Empirical Assessment of the Public's Willingness to Participate and Implications for Recruitment Strategy
Kelsey Moriarty

Utilization Management

B-356 Keeping an Eye on Utilization Management: Cost Reduction of Inherited Retinal Dystrophy Genetic Testing through the Incorporation of CNV Detection via Next Generation Sequencing
Megan Nelson

GROUP C POSTERS

Access and Service Delivery

C-3 Service Delivery Model Interests, Needs and Barriers Reported by Genetic Counselors
Emily Boothe

C-6 Accessibility of Pregnancy Termination: A Pilot Study of Genetic Counselors and Abortion Providers throughout the United States
Lauren Facchini

C-9 Changes in Service Delivery Model Use among Genetic Counselors from 2010 to 2017
Samantha Greenberg

C-12 Spanish-speaking Limited English Proficient Patients and the Roles of Interpreters in the Medical and Metabolic Genetics Clinics
Daisy Hernandez

C-15 Assessing the Need and Desire for Cancer Genetics Education Among Rural Healthcare Providers
Bailey Hulswit

C-18 Implementing Next-generation Sequencing in Post Mortem Cases of Sudden Cardiac Death: A Public Health Laboratory Perspective
Kimberly Anderson

C-21 Who is Providing Genetic Counseling around the World?
Brittney Meays

C-24 Genetic Testing Outcomes by Race: Observations from Michigan's Hereditary Cancer Network
Andrea Murad

C-27 Developing and Implementing a Policy to Allow Patients Access to Their Genomic Data
Ebony Richardson

C-30 Experience with Healthy Individuals Pursuing Genomic Screening: Providing Guidance for Genomic Counseling via a Telemedicine Approach
Betsy Swope

Adult

C-33 Huntington's Disease Diagnosis without a Known Family History
Tanya Bardakjian

C-36 Assessing the Barriers to Cardiac Care in Carriers of Duchenne and Becker Muscular Dystrophy
Lauren Eekhoff

C-39 Clinical Utility of Whole Exome Sequencing in Adult Medical Genetics Patients: A Case Series
Lauren Hipp

C-42 Applying Maslow's Hierarchy of Needs to Understand the Socio-emotional Experiences of Adults with an Intellectual Disability
Erin Nordquist

Cancer

C-45 Patient Attitudes toward Genetic Testing for Inherited Predispositions to Hematologic Malignancies
Taylor Beecroft

C-48 Breast and Ovarian Cancer Screening Behaviors and Health Outcomes After Genetic Testing
Austin Chua

C-51 Panel Testing in the Setting of a Familial Cancer Gene Mutation: Finding Unexpected Results
Samantha Culver

C-54 A Comparison of Cancer Risk and Clinical Management of Female Carriers of *CHEK2* Truncation and Missense Mutations
Sojin Durrant

C-57 A Comparison of Genetic Counseling Referral Criteria to a Population of Renal Cell Carcinoma Patients: Current Criteria Miss Patients with a Hereditary Cancer Predisposition
Remington Fenter

C-60 Perspectives on Information Desired During Genetics Evaluation: A Qualitative Analysis of Men with Prostate Cancer
Samantha Greenberg

C-63 Genetics Referral and Utility in Tumor Only Breast Tumor Genomic Profiling: One Institution's Experience
Austin Huber

C-66 Assessing the Discordant Classification Rate for *ATM*, *CHEK2*, and *PALB2* Variants in ClinVar
Sayoni Lahiri

C-69 Clinical Implications for Individuals with Multiple Pathogenic Variants in Cancer Predisposition Genes
Melanie Baxter

C-72 Wnt Pathway and Craniopharyngioma: Clues for Cancer Predisposition
Rose McGee

C-75 Trends and Outcomes of Genetic Testing in Probands with Prostate Cancer
Jenae Osobrne

C-78 *MSH2* Mutation Identified via Somatic Testing in Primary Anaplastic Glioneuronal Tumor Leads to Diagnosis of Lynch Syndrome
Krista Qualmann

C-81 Clinical Challenges of VUS Findings in Families Highly Suspicious for Lynch Syndrome
Dianne Samad

C-84 Striving to Fulfill a Duty to Recontact – Efficacy of Mailed Letters
Lindsey Sawyer

C-87 Association of Breast Cancer by Pathogenic *CHEK2* Variant Type
Lily Servais

C-90 Family and Provider Comfort with Pharmacogenetic Testing for a Pediatric Oncology Population
Joyce Turner

C-93 Utilization of Statistical Breast Cancer Risk Prediction Models by Genetic Counselors in Clinical Practice
Min Seon Park

Are guidelines missing patients?

10.5% positive rate for patients **in criteria**

9.0% positive rate for patients in **out of criteria**

In a study of 4,196 Medicare cancer patients published in the *Annals of Surgical Oncology*, Invitae found that positive results are nearly as high in patients who did not meet criteria for testing as in patients who met criteria.[1]

1. Yang S *et al. Ann Surg Oncol.* 2018;25(10):2925-31.

INVITAE

© 2018 Invitae Corporation. All Rights Reserved. | www.invitae.com/contact

Visit us at **BOOTH 703** to learn more

Posters With Authors (continued)

C-96 Cancer Genetic Counselors' Experiences with Transgender Patients: An Exploratory Qualitative Study
Kimberly Zayhowski

Cardiology

C-99 Factors That Are Predictors of Recommendation Adherence Among Carriers of Dystrophinopathies
Jessica Goldsberry

C-102 The Value of Post-mortem Genetic Testing in Individuals with Sudden Death in a Large Urban Setting: A Custom Cardiovascular Genetics Panel in an Internal Molecular Genetics Laboratory at a Medical Examiner's Office
Elizabeth Manderski

C-105 Comprehension of Uninformative Genetic Testing Results in Hypertrophic Cardiomyopathy and Suggestions for an Improved Report Supplement
Brooke Nightingale

C-108 Family Experiences of Inpatient Genetic Counseling for Infant Congenital Heart Defects and Cardiomyopathies: A Qualitative Pilot Study
Victoria Schwarzinger

C-111 Balanced Translocation Disrupting *SCN5A* in a Family with Brugada Syndrome and Sudden Death
Laura Yeates

Counseling/Psychosocial Issues

C-114 The Impact of the Counseling Environment on Patient Outcomes of Genetic Counseling
Jacob Best

C-117 Is It Feasible? Self-affirmation For Hereditary Breast and Ovarian Cancer Genetic Counseling
Anna Chassevent

C-120 Quality of Life and Adaptation in Individuals with Inherited and Sporadic Facial Palsy: Opportunities for Genetic Counseling
Flavia Facio

C-123 Examining the Relationship Between Genetic Counselors' Implicit Attitudes toward Disability and Their Practice Methods
Helen Gould

C-126 A Qualitative Investigation of Parents' Information and Support Needs When Their Child is Diagnosed with Alopecia Areata
Alexandria Holcomb

C-129 Parental Perception of and Experience with Uncertain Results from Pediatric Whole Exome Sequencing
Xin Li

C-132 Correlation between Illness Perception and Perceived Utility of a Support Group Among Affected Individuals and Unaffected Parents of Children with Marfan Syndrome
Amy Malinowski

C-135 Evaluation of the Support Provided to Male *BRCA1/2* Mutation Carriers: Are Their Needs Being Met or Can Genetic Counselors Do Better?
Anna-Lena Nassar

C-138 Does an Individual's Perceived Severity of Their Positive Genetic Test Results Influence Whether They Post about It on a Social Media Site?
Kaitlyn Riley

C-141 Concerns and Perspectives from Families with Hereditary Pancreatitis
Celeste Shelton

C-144 The Personal Utility of a Genetic Etiology for Developmental Brain Disorders in Adult Research Participants
Karen Wain

Education

C-147 How Do We Get There and Will We be Prepared? Clinician Perspectives on Elective Genome Sequencing
Liana Dayhoff

C-150 Who is Engaging in Precision Medicine Education? An Exploratory Analysis of Online CME Data
Emily Edelman

C-153 Does a Diagnosis Make a Difference? Examining the Utility of Etiology-based Information for Teachers of Children with Neurogenetic Syndromes
Dana Jarvis

C-156 Exploring a Brief Medical Improvisational Performing Arts Intervention for Genetic Counseling Graduate Students
Weilong Li

C-159 Development and Initial Assessment of a Pharmacogenetics Education Module for Genetic Counseling Students
Rachel Mills

C-162 Understanding Genetics Learning Needs of People Affected by Rare Disease
Laura Quinn

Ethical, Legal and Social Issues

C-165 Review of the Present State of and Challenges for the Return of Genomic Research Results in the Japanese Medical Service System
Yayoi Aizawa

C-168 Assessing Genetic Counselors' Experiences with Physician Aid-in-dying and its Implication to Our Practice
Abby D'Angelo

C-171 Adolescent Perspectives on Genetic Testing for Huntington's Disease
Alanna Rahm

C-174 Systematic Ethical Framework for Evaluating and Rejecting the use of Genotype-targeted Advertising
Misha Rashkin

C-177 "They're Not Going to Do Nothing for Me:" The Role of Genetic Counselors in the Future of Genomic Testing
Erica Sutton

Genetic/Genomic Testing

C-180 Genetic Counseling following Consumer Driven Genetic Testing: Who, What and Why
Sharon Reid Altmeyer

C-183 A Data-driven Approach for Determining Conditions to Include in Expanded Carrier Screening Panels
Rotem Ben-Shachar

C-186 Negative Whole Exome Sequencing...Now What?
Elly Brokamp

C-189 Personal Genetic Testing for Future Genetic Counselors: Assessing Interest in Offering Personal Genetic Testing as an Educational Experience in Genetic Counseling Graduate Programs
Brian Corner

C-192 Unexpected Findings via Fragile X Carrier Screening, Four Case Reports
Casey Duld

C-195 Mate-pair Sequencing: Providing Molecular Resolution of Structural Rearrangements for Improved Diagnostic Clarity
Anna Essendrup

C-198 *NCAM2*: A Candidate for Corpus Callosum Malformation
Marcela Hanna

gem Genetic Education Module

GEM is an interactive site including videos, narratives, and tools designed to educate your patients and staff about genetic testing options. The goals of GEM are to reduce clinic time spent on routine education, to educate office staff to answer basic questions, and to provide useful tools to describe risk, and compare and contrast testing options.

After reviewing the Genetic Education Modules …

1. **Providers will be able to answer patient questions and provide non-directive information about prenatal testing options.**
2. **Providers will be able to use the time available for patient counseling more efficiently.**
3. **Patients will appreciate their personal responsibility in making decisions about prenatal testing.**

Perinatal Quality Foundation | www.perinatalquality.org

Posters With Authors (continued)

C-201 Assessment of a Video on Genome Testing Expectations and Results: Parent and Adolescent Views and Understanding
Michaela Idleburg

C-204 Interpretation of Microdeletion Variants Aided by Population Analysis of Copy-number Variation
Kristjan Kaseniit

C-207 Participants' Perceptions of Sequencing Accuracy and Its Correlations with Knowledge, Numeracy and Optimism
Katie Lewis

C-210 Removing the Barrier of Cost for Family Variant Testing in Cancer Predisposition Genes Significantly Increases Uptake Among Relatives
Rachel F. Miller

C-213 Newborn Screening for Fabry Disease – Implications of Presymptomatic Diagnosis for a Lysosomal Storage Disease with Phenotypic Heterogeneity
Haley Nisson

C-216 Adherence to NCCN Guidelines Within One Hospital System: Comparison between Sites and Genetic Counselor Utilization
Karen Powell

C-219 Patient-derived Genomic Data from ClinGen's GenomeConnect: Advancing Genomic Knowledge and Keeping Patients Informed of Variant Classifications
Juliann Savatt

C-222 Delay of Diagnosis: The Impact of a Lack of Physician Contact Information and Clinical History in Biochemical Genetic Test Result Interpretation
April Studinski

C-225 Exploring the Impact of Pharmacogenomic Results on Medical Management and Disclosure Behaviours
Allison Hazell

C-228 Custom Reporting Structure for Accurate Risk Assessment of *NPHS2*-related Nephrotic Syndrome in Counsyl's Foresight Carrier Screen
Domenic Previte

Other

C-231 A Needs Assessment of Genetic Counseling in Mexico
Daiana Bucio

C-234 Do Labels Matter? Alternative Option Labeling Impacts Decision Making In Non-invasive Prenatal Screening
Camille Fisher

C-237 Genetic Counselors' Discussion of Parkinson's Disease Risk in Gaucher/Metabolic Clinics
Anne Nyberg

Pediatrics

C-240 *CDC42*: A Candidate Gene for Neurodevelopmental Disorders
Diana Bertrand

C-243 Pediatric Experience of Prenatally Identified 45,X/46,XY Males
KT Curry

C-246 Growth Parameters at Birth in Patients with Mucopolysaccharidosis: Large-scale Newborn Screening Program in Taiwan
You-Hsin Huang

C-249 Characterizing the Phenotypic Presentation of an International Sample of 48, XXXY and 49,XXXXY, two rare variants of 47, XXY (Klinefelter Syndrome) and the Impact of Testosterone Replacement Therapy (TRT)
Patricia Lasutschinkow

C-252 The Psychiatric Impact of Tuberous Sclerosis Complex and Utilization of Mental Health Treatment
Kate Mowrey

C-255 "Familial Immune Thrombocytopenia" Correctly Identified as Familial Platelet Disorder with Propensity to Acute Myeloid Leukemia due to *RUNX1* c.1163C>A (p.S388*)
Kelly Rich

C-258 Is Bigger Really Better? Reviewing the Utility of a >2000-Gene Sequencing Panel for Developmental Disabilities in Our Pediatric Institution
Megan C. Sikes

C-261 Making a Genetic Diagnosis in a Level IV Neonatal Intensive Care Unit Population: How Many do We Find and How Long Does it Take?
Kayleigh Swaggart

Pre- and Perinatal

C-264 Prenatal Diagnosis of 47,XX,+der(14)t(14;17)(q11.2; p12): A Child of a Balanced Translocation Carrier and a 3:1 Segregation
Hannah Anderson

C-267 Clinical Impact and Cost Effectiveness of a 176 Condition Expanded Carrier Screen
Kyle Beauchamp

C-270 Uptake of Carrier Screening Among Male Reproductive Partners of Prenatal and Preconception Patients: A Retrospective Review
Meagan Choates

C-273 Exploring Positive Diagnostic Results after Receiving "Aneuploidy Suspected" Screen Results via Non-invasive Prenatal Screening
Amy Dexter

C-276 Aneuploidy Screening in the Antenatal Testing Unit at Boston Medical Center: Assessing the Context of Decision Making Around Non-invasive Screening Options
Jessica Fallon

C-279 How Many Carriers are Being Missed? A Comparison of Traditional Carrier Screening Methodologies and Whole Gene Comprehensive Methodologies for Cystic Fibrosis and Spinal Muscular Atrophy
Heather Fecteau

C-282 Cell-free DNA for Sex Chromosome Anomalies, Copy Number Variants and Single Gene Disorders: The Experiences of Prenatal Genetic Counselors
Katrina Flynn

C-285 Assessing Perinatal Palliative Care Education within Genetic Counseling Training Programs
Meg Hager

C-288 Clinical Utility of Preconception Expanded Carrier Screening
Katie Johansen Taber

C-291 Whole Exome Sequencing Reveals Novel *USP9X* Mutation in Female Fetus with Isolated Agenesis of the Corpus Callosum
Jerica Lenberg

C-294 Understanding Preconception Couples' Perceived Use of Information from Expanded Carrier Screening
Ashlie Miller

C-297 Does Eating Placenta Help with Postpartum Mood, Energy and Breastfeeding? A Matched Cohort Study of Postpartum Placentophagy Outcomes to Inform Prenatal Genetic Counseling
Emily Morris

C-300 Prenatal Detection of a Cryptic Derivative Chromosome: Association of Ultrasound Findings with an Imprinted Region
Christine Riordan

C-303 Prenatal Diagnosis of the 15q11.2 Microdeletion: Challenges for Genetic Counseling and Parental Decision Making
Katelynn Sagaser

C-306 2q12.2q13 Microdeletion Segregating in a Family with Agenesis of the Corpus Callosum
Laurie Simone

C-309 Making Sense of Patients' Decision Making and Needs within the Context of Noninvasive Prenatal Testing
Lauren Turner

C-312 Whose Y Is it Anyway? Transplants and NIPT II
Michelle Hackbardt

C-315 Withdrawn

Professional Issues

C-318 Perceived Stress and Job Satisfaction: A Comparison of Laboratory and Clinical Genetic Counselors
Brittany Brassell

C-321 Exploring Genetic Counseling Information Needs and Information Seeking Behaviors
Amy Donahue

C-324 Defining the Role of a Genetic Counselor Within Comprehensive Care Teams: Perspectives of the Provider Team and Patients
Paul Hudson

C-327 Factors Influencing Risk of Burnout in Genetic Counselors
Emily Lancaster

C-330 How is The NSGC Definition of Genetic Counseling Being Used?
Robert Resta

C-333 Academic Appointment for Genetic Counselors: Opportunities, Challenges and Career Trajectories
Yiru Zhao

Psychiatry/Neurology

C-336 22q11.2 Deletion Syndrome: Psychiatrist Self-report of Knowledge of Mental Health Implications and Willingness to Act in Providing Clinical Services
Natalie Dykzeul

C-339 Perspectives on Spinraza (Nusinersen) Treatment (POST) Study: Views of Individuals and Parents of Children Diagnosed with Spinal Muscular Atrophy
Michelle Pacione

C-342 Scope of Neurogenetic Counselors' Practice
Carly Siskind

C-345 Genetic Testing Practices of Genetic Counselors, Geneticists and Pediatric Neurologists with Regard to Childhood-onset Neurogenetic Conditions
Sara Wofford

Public Health

C-348 Evaluation of Parents' Experiences when a Child Receives a Positive Newborn Screening Result for Mucopolysaccharidosis Type I (MPS I)
Kathryn DeLong

Posters With Authors (continued)

Research Issues

C-351 Use of a GeneMatcher Platform to Facilitate Connections Between Laboratories, Clinicians and Researchers Interested in Candidate Genes

Laura Fisher

C-354 Feasibility, Acceptability and Face Validity of a Novel, Brief, Web-based Simulation Tool for Assessing Genetic Counseling Communication

Michael Setzer

Utilization Management

C-357 Perimortem Genetic Testing in a Children's Hospital: A Case for Policy Development

Darci Sternen

A breakthrough in prenatal screening

Maternal Fetal Screen℠ I T1 is the most comprehensive first-trimester screening test available, combining ultrasound measurements with the analysis of five biochemical markers to provide quantitative risk assessments for trisomies 21, 18, and 13 and early onset preeclampsia.

Identify at-risk patients sooner with comprehensive first-line screening. Learn more at ntd-eurofins.com.

Coming to the 2018 NSGC conference? Visit us at booth 713!

NTD | Eurofins Clinical Diagnostics

This test is a part of a lab service offering provided by NTD. This test was developed and its performance characteristics determined by NTD. It has not been cleared or approved by the U.S. Food and Drug Administration. The methods and performance characteristics have been reviewed and approved by the New York State Department of Health.

Copyright ©2018, Eurofins NTD, LLC. All rights reserved. NTD Labs is a registered trademark of Eurofins Scientific. All other trademarks are the property of their respective owners. Printed in USA

Vendor Sponsored Presentations

Vendor-sponsored presentations are 30-minute presentations given by select vendors in the Vendor Theater located in the NSGC Central area of the Exhibitor Suite. These presentations are a great way to learn more about new products and services. Make the most of your time in the Exhibitor Suite by attending one of the following presentations:

Wednesday, November 14

6:30 pm – 7:00 pm

AstraZeneca

Homologous Recombination Deficiency and *BRCA* Testing in Ovarian and Breast Cancer

Sandra Indiviglio, Ph.D.

This presentation will include an introduction to DNA damage repair and the role of homologous recombination deficiency (HRD) in cancer. The presentation will focus on *BRCA* mutations as an underlying cause of HRD and discuss the rationale and process for *BRCA* testing, generally, and in ovarian and breast cancer, specifically.

7:15 pm – 7:45 pm

SANOFI GENZYME

The Case for Cerdelga® (eliglustat) capsules: The ONLY First-line Oral Treatment for Most Adult Patients with Gaucher Disease Type 1 Indicated for Long-term Treatment of Both Naïve and Switch Patients

Carlos E. Prada, MD

This symposium will provide brief overview of Gaucher disease type 1 and its long-term management. Attendees will briefly review treatment options and case studies exploring factors that support selection of Cerdelga as a first-line oral long-term treatment choice for appropriate adult Gaucher type 1 patients.

Thursday, November 15

12:00 pm – 12:30 pm

Boulder Abortion Clinic

Termination of Pregnancy for Indications of Genetic Disorder and Fetal Abnormality in Advanced Gestations

Catherine Chalecki

The diagnostic categories of fetal anomalies and genetic disorders for patients seen over a period of 35 years will be presented. The components of clinical care for patients seeking this service will be presented including preoperative evaluation, protocol for management of patients in different stages of pregnancy, operative techniques, postoperative management and evaluation, and procedures for grief support.

12:45 pm – 1:15 pm

color

Clinical Counseling in the General Population: Lessons Learned

Lauren Ryan, MS, LCGC

As part of Color's mission to increase access to genetic counseling and testing, multi-gene panel tests are available to a broader population than in traditional clinics. Importantly, genetic counseling is offered to all clients at no additional charge. This creates unique counseling situations and opportunities to apply clinical skills to a new segment of the general population, which will be reviewed as a series of case studies to highlight themes and challenges identified in over 10,000 counseling sessions.

6:00 pm – 6:30 pm

Greenwood Diagnostic Labs
Giving Greater Care

Getting to the Diagnosis QUICKly: A Patient-focused Approach

Kellie Walden, MS, CGC and Mike Friez, PhD, FACMG

Giving Greater Care means we strive to develop strategies that put the patient first. With innumerable genetic testing options available today, we suggest a fast, cost effective approach with a high diagnostic yield as we review our experience with various molecular tests, including multigene panels, whole exome sequencing, custom tests requests, and the QUICK analysis.

7:00 pm – 7:30 pm

SANOFI GENZYME

Fabry Disease: Know When to Treat

Maryam Banikazemi, MD

Fabry disease is a rare, silently progressive and often life-threatening X-linked genetic disorder caused by a defect in the gene for the lysosomal enzyme α-galactosidase A (α-GAL). Dr. Banikazemi will discuss recent treatment recommendations and guidelines for the diagnosis and treatment of Fabry patients to ensure optimal outcomes.

Friday, November 16

12:30 pm – 1:00 pm

PerkinElmer For the Better | PerkinElmer GENOMICS

Clinical Whole Genome Sequencing: Using Innovative Technology and Genomic Expertise to Change the Paradigm of Clinical Genomics

Alice K. Tanner, PhD, MS, CGC, FACMG

PerkinElmer Genomics is helping change the paradigm in clinical genomic testing by applying the latest in technology with genomic expertise. We are one of the first labs to develop a variety of clinical whole genome sequencing (WGS) tests to positively influence patient diagnosis. Discover more with NGC.

NSGC Thanks Our Year-Round Sponsors

PLATINUM

Ambry Genetics®
A Konica Minolta Company

AstraZeneca

GOLD

Amicus Therapeutics

INVITAE

SILVER

NTD | Eurofins Clinical Diagnostics

Pfizer Oncology

NSGC Thanks Our Annual Conference Sponsors

PLATINUM

INVITAE

myriad®

GOLD

Ambry Genetics®
A Konica Minolta Company

GeneDx
an OPKO Health Company

SILVER

illumina®

BRONZE

Alnylam® PHARMACEUTICALS

BAYLOR GENETICS

BOULDER ABORTION CLINIC

Counsyl

EGL Genetics | Eurofins Clinical Diagnostics

Integrated GENETICS
LabCorp Specialty Testing Group

PerkinElmer
For the Better

PerkinElmer GENOMICS

PREVENTION GENETICS
DISEASE PREVENTION THROUGH GENETIC TESTING

SANOFI GENZYME

EDUCATIONAL SUPPORT

METIS GENETICS

RARE SCIENCE, INC. – RARE BEAR SPONSOR

illumina®

NSGC Awards

Fellowships and Special Project Awards

JANE ENGELBERG MEMORIAL FELLOWSHIP AWARD (JEMF)

Colleen Caleshu, ScM, LCGC
MaryAnn Campion, EdD, MS, LCGC

AUDREY HEIMLER SPECIAL PROJECT AWARD (AHSPA)

Andrea Durst, MS, DrPH, LCGC
Kunal Sanghavi, MBBS, MS, LCGC
Rebecca Vanderwall, MS, MPH, LCGC
Raluca N. Kurz, MS, LCGC

NSGC Leadership Awards

NATALIE WEISSBERGER PAUL NATIONAL ACHIEVEMENT AWARD

Cindy E. Soliday, MS, LCGC

NEW LEADER AWARD

Aishwarya Arjunan, MS, MPH, CGC, CPH
Rebekah Moore, MS, LGC

OUTSTANDING VOLUNTEER AWARD

Rachel Mills, MS, CGC

CULTURAL COMPETENCY AWARD

Priscila Delgado Hodges, MS, CGC

STRATEGIC LEADER AWARD

Colleen A. Campbell, PhD, MS, CGC

Best Abstract Awards

BEST FULL MEMBER ABSTRACT AWARD

Group Telehealth Appointments for Cancer Counseling Increase Genetic Counselor Efficiency

Renee Rider, JD, MS, LCGC

BETH FINE KAPLAN STUDENT ABSTRACT AWARD

Ethnic Disparities in the Frequency of Cancer Reported in Family Histories

Heather Maves, MS, MB (ASCP)

Scholarship and Journal Awards

JOURNAL OF GENETIC COUNSELING BEST PAPER TRAINEE ONLY CATEGORY

Anthony Chen
Daniella Kamara

JOURNAL OF GENETIC COUNSELING BEST PAPER GENERAL TRAINEE CATEGORY

Krista Redlinger-Grosse
Susan Christian

STUDENT ANNUAL CONFERENCE SCHOLARSHIP

Katherine Ross
Joanna Urli

SAVE THE DATE

NSGC's Business Meeting

Thursday, December 6, 2018

1:00 pm ET/12:00 pm CT/11:00 am MT/10:00 am PT

Register at **www.nsgc.org/2018businessmeeting**

Annual Conference Program Committee

NSGC expresses its gratitude to these volunteers for their hard work and dedication:

Chair
Colleen Schmitt, MS, CGC

Vice Chair
Katherine Lafferty, MS, CGC

COMMITTEE MEMBERS
Carrie Blout, MS, CGC
Colleen Caleshu, MS, LCGC
Melanie Hardy, MS, MS, LCGC
Katie Krepkovich, MS, MS, CGC
Lauren Lichten, MS, CGC
Rachel Mills, MS, CGC
Margaret Sheehan, MS, CGC
Emily Smith, MS, CGC
Barry Tong, MS, CGC

Absract Workgroup

Abstract Workgroup Chair
Margaret Bradbury, MS, CGC, MSHS

Abstract Workgroup Vice Chair
Courtney Berrios, MS, CGC

Past Chair
Taylor J. Berninger, MS, MA, MEd, LCGC

ABSTRACT WORKGROUP MEMBERS
Kathleen Aaron, MS
Carrie Atzinger, MS, CGC
Sharon Aufox, MS
Danielle Azzariti, MS, CGC
Riyana Babul-Hirji, MSc, CGC
Tanya Bardakjian, MS, CGC
Karlla Brigatti, MS, LCGC
Jennifer Brzosowicz, MS, CGC
Carrie Castonguay, MS, CGC
Julie Culver, MS, LCGC
Kyle W. David, ScM, LCGC
Kelly East, MS, CGC
Emily Fassi, MS, LGC
Sara Fitzgerald-Butt, MS, LGC
Kate Foreman, MS, CGC
Caitlin Grabarits, MGC, LCGC
Tracey Grant, MS
Yue Guan, PhD, ScM
Maria Gyure, MS, LCGC
Stephanie Harris, CGC
Meadow Heiman, MS, LCGC
Katherine Helbig, MS, LCGC
Jodie Ingles, GDCD, MPH, PhD
Michelle Jacobs, MS, CGC
Yelena Kemel, MS, ScM, CGC
Sara Knapke, MS, LCGC
Jessica Laprise, MS, CGC
Gabriel Lazarin, MS, CGC
Amy Lemke, MS, PhD
Katie Lewis, ScM, CGC
Khalida Liaquat, MS, LCGC
Meghan Lundy, MS, LCGC
Elizabeth Lutz, MS, LCGC
Megan Marshall, MS, LCGC
Jessica Mester, MS, LCGC
Erin Miller, MS, CGC
Chinmayee Nagaraj, LGC
Sarah Noblin, MS, CGC
Kailey Owens, MS, CGC
Vivian Pan, CGC
Ashley Parrott, MS, LGC
Emily Partack, MS, CGC
Zöe Powis, MS, CGC
Andrea Procko, CGC
Betsy Peach, MS, CGC
Lauren Propst, MS, CGC
Irene Rainville, MS, PhD
Victoria Raymond, MS
Chloe Reuter, MS, CGC
Kathleen Collins Ruff, MS, LGC
Gretchen Schneider, MS, LCGC
Jennifer Schwab, MS, CGC
Sarah Scollon, MS, CGC
Kate Shane-Carson, MS, LGC
Morgan Similuk, ScM, CGC
Katherine Skora, MS, MPH, CGC
Jill Slamon, MA, MS, LCGC
Christopher Tan, MS, LCGC
Devon Lamb Thrush, MS, CGC
Elizabeth Ulm, MS, CGC
Karen Wain, MS, LGC
Chani Wiesman, MS, CGC
Sarah Yarnall, MS, CGC

Networking Activities + Meetings

Welcome to the Annual Conference: First-time Attendee Orientation

WEDNESDAY, NOVEMBER 14
2:00 pm – 3:15 pm
Room A411

Are you a first-time Annual Conference attendee? Make your way to this event to network with other new attendees and learn about the Annual Conference. The second half of the SIG Fair will be just for first-time attendees and new NSGC members. Meet with SIG leaders at this event and learn more about what NSGC's SIGs have to offer.

NSGC SIG Fair

WEDNESDAY, NOVEMBER 14
2:00 pm – 3:15 pm
Room A412

All Annual Conference attendees are invited to the NSGC Special Interest Group (SIG) Fair to meet with SIG leaders and to learn more about current SIG projects and how you can become involved. The first half of the SIG Fair is open to all conference attendees. The second half will be dedicated to first-time attendees.

Welcome Reception

WEDNESDAY, NOVEMBER 14
5:30 pm – 8:30 pm
Exhibit Hall C1/C2

Make new contacts and greet your friends as you preview the vendors and their services in the Exhibitor Suite. Join your colleagues for this special kickoff to the Annual Conference. Light hors d'oeuvres and a cash bar will be available.

NSGC State of the Society Address

THURSDAY, NOVEMBER 15
8:35 am – 9:35 am
Georgia Ballroom

Join NSGC President Erica Ramos, MS, CGC, as she shares NSGC activities and accomplishments over the past year, reviews NSGC's advocacy efforts and strategic initiatives.

Incoming Presidential Address

THURSDAY, NOVEMBER 15
9:35 am – 10:05 am
Georgia Ballroom

Welcome NSGC President-Elect Amy Sturm, MS, CGC, LGC, as she introduces herself to NSGC members and outlines her vision for NSGC and the genetic counseling profession in 2019.

American Board of Genetic Counseling (ABGC) Annual Business Meeting

FRIDAY, NOVEMBER 16
12:30 pm – 1:30 pm
Georgia Ballroom

Accreditation Council for Genetic Counseling (ACGC) Presentation

FRIDAY, NOVEMBER 16
1:00 pm – 1:30 pm
Georgia Ballroom

2018 Code Talker Award

FRIDAY, NOVEMBER 16
6:45 pm – 8:45 pm
Room A411-A412

Join us for an evening of food, drinks, and amazing stories at the 2018 Code Talker Award, honoring genetic counselors nominated by the families they serve.

Registration is required, check at the registration desk for availability.

Presented by: INVITAE

Meals + Refreshments

Continental breakfast will be served Thursday – Saturday in the Georgia Ballroom Foyer and in the Building C Level One and Level Two Foyers on Wednesday from 7:00 am – 8:00 am.

Refreshment Breaks

WEDNESDAY, NOVEMBER 14
10:00 am – 10:30 am, C100 Foyer and C200 Foyer
**Pre-conference attendees only*

THURSDAY, NOVEMBER 15
10:05 am – 10:45 am, Exhibit Hall C1/C2
1:15 pm – 1:45 pm, C100 Foyer and C200 Foyer

FRIDAY, NOVEMBER 16
10:05 am – 10:45 am, Exhibit Hall C1/C2
4:40 pm – 5:00 pm, Georgia Ballroom Foyer

SATURDAY, NOVEMBER 17
9:50 am – 10:10 am, C100 Foyer and C200 Foyer

NSGC gratefully acknowledges our Refreshment Break Sponsor

myriad

Join Us at the Booths Below for a Special Treat

The following vendors are generously serving snacks at their booth at the following times. Be sure to stop by while supplies last.

WEDNESDAY, NOVEMBER 14
5:30 pm – 8:30 pm

Booth #1134

American Board of Genetic Counseling, Inc. ABGC

Booth #703

INVITAE

THURSDAY, NOVEMBER 15
10:05 am – 10:45 am

Booth #1025

myriad

Booth #533

RPRD DIAGNOSTICS
Right Patient | Right Drug

3:45 pm – 4:15 pm

Booth #703

INVITAE

Booth #1025

myriad

5:30 pm – 8:00 pm

Booth #1025

myriad

FRIDAY, NOVEMBER 15
10:00 am – 10:45 am

Booth #703

INVITAE

This is LIVING with cancer™

LINDSAY N, LIVING WITH CANCER SINCE 2016

Today, more people than ever are managing life with cancer

LivingWith™ is a free app for people living with cancer. Designed to help you connect with loved ones, ask for the support you need, remember important information from doctors' visits and stay organized, all in one place.

Text "**NSGC**" to **70989** to download **LivingWith** for free.

ThisIsLivingWithCancer.com

Download on the App Store

GET IT ON Google Play

You will receive one autodialed marketing message per request. Message & data rates may apply. Text "HELP" for additional support. Terms & Conditions: ThisIsLivingWithCancer.com/termsandconditions. Reply "STOP" to cancel. App Store is a service mark of Apple Inc., registered in the U.S. and other countries. Google Play and the Google Play logo are trademarks of Google LLC.

Pfizer Oncology

We're Working to Redefine Life with Cancer

PP-ONC-USA-1104 © 2018 Pfizer Inc. All rights reserved. Printed in USA/September 2018

Exhibitor Directory by Company Name

23andMe 1011
AbortionClinics.Org, Inc./AAF, Inc. 602
Admera Health 519
Advanced Tele-Genetic Counseling (AT-GC) 1133
AliveAndKickn 1214
Allele Diagnostics 431
Alnylam Pharmaceuticals 1033
Alpha-1 Foundation 534
Ambry Genetics 829
American Board of Genetic Counseling (ABGC) 1134
American Society of Human Genetics 1232
Amicus Therapeutics 1016
ARUP Laboratories 615
AstraZeneca 610
AveXis, Inc. 536
AXYS 435
Basser Center for BRCA 1109
Batten Disease Support and Research 1227
Baylor Genetics 525
Biogen 1132
BioMarin Pharmaceutical, Inc. 718
Blueprint Genetics Inc. 732
Boulder Abortion Clinic, PC 708
Cancer IQ, Inc 1136
Capital Women's Services 936
CBR a California Cryobank Company 1229
Celmatix 510
Center for Fetal Diagnosis and Treatment (CHOP) 934
Centogene US, LLC 632
ClinGen 513
Color 1129
Concert Genetics 1026
Connective Tissue Gene Tests 917
CooperGenomics 933
Counsyl a Myriad Genetics Company 1015
Covenant Health 1115
DNA Genotek 512
EGL Genetics 834
FamHis, Inc. 637
FORCE: Facing Our Risk of Cancer Empowered 1135
Fulgent Genetics 524
Geisinger 427
Gene42, Inc. 1230
GeneDx Inc. 809
GeneMatters 709
Genetic Support Foundation 508
Geneveda 607
Genome Magazine 1226
Genome Medical 1119
GenPath Women's Health 808
Greenwood Genetic Center 616
Igenomix 1228
Illumina, Inc. 515
InformedDNA 535
Integrated Genetics 617
Invitae 703
Invitae Photo Booth 706
Johns Hopkins Center for Fetal Therapy 526
Johns Hopkins Genomics 428
JScreen at Emory University 412
Kaiser Permanente Northern California 711
Laboratory for Molecular Medicine – Partners Personalized Medicine 517
Le Bonheur Children's Hospital 437
Lettercase: National Center for Prenatal and Postnatal Resources 408
MNG Laboratories 504
Myriad Genetic Laboratories, Inc. 1025
National Coordinating Center for the Regional Gene 424
National Down Syndrome Congress 1233
NCATS/Genetic Rare Diseases Information Center 1212
NIH Genetic Testing Registry/MedGen/ClinVar 700
Northside Hospital Cancer Institute Cancer Genetic Program 601
Norton & Elaine Sarnoff Center for Jewish Genetics 1125
Norton Healthcare 1210
Now I Lay Me Down To Sleep 433
NSGC Central 818
NSGC Job Board 724
NTD Eurofins 713
Organization of Teralogy Information Specialists/MotherToBaby 1234
Parent Project Muscular Dustrophy/Decode Duchenne 410
PerkinElmer Genomics 417
Pfizer Oncology 1113
Phosphorus Diagnostics 411
PreventionGenetics 907
Progenity 509
Progeny Genetics 937
Quest Diagnositcs 729
RARE Science, Inc. – RARE Bear Sponsor 432
Rare Genomes Project (Broad Institute) 430
Recordati Rare Diseases 812
Retrophin, Inc. 1111
Roche Diagnostics 1006
RPRD Diagnostics 533
Sanford Research – CoRDS Registry 737
Sanofi Genzyme 600
Sarepta Therapeutics 1105
Seattle Children's Hospital – PLUGS 625
Sema4 1108
Sharsheret 1127
Shire 532
Simons VIP Connect 530
Southwestern Women's Options 1117
Special Angels Adoption 1107
St. Jude Children's Research Hospital 1216
Stealth BioTherapeutics 405
Texas Children's Pavilion for Women – Fetal Center 736
The Children's Hospital of Philadephia 426
The Focus Foundation 735
The Marfan Foundation 1235
ThinkGenetic, Inc. 1014
TrakGene 425
UAB Medical Genomics Laboratory 614
UCLA Health 1018
UCSF Fetal Treatment Center 627
Undiagnosed Diseases Network (UDN) 407
University of Chicago Genetic Services Laboratories 716
University of Washington 1024
UNMC Human Genetics Laboratory 925
UPMC 1231
Valley Children's Healthcare 429
Variantyx, Inc. 835
Women's Care Florida 528

Exhibitor Map



Exhibitor Index

23andMe
Booth 1011
408.489.8683
www.23andme.com

Founded in 2006, 23andMe is the first and only genetic service available directly to consumers that offers over 90 reports on your genetic health risks, wellness, traits and ancestry that meet FDA requirements.

AbortionClinics.Org/Abortion Access Fund, Inc.
Booth 602
888.684.3599
info@arhc.online
www.abortionclinics.org

Our mission at AbortionClinics.Org is to provide pregnancy terminations, contraception and routine medical care to all patients in a compassionate, comfortable and personal environment. Abortion Access Fund is a non-profit fund that was established to help fund our patients with the cost of their procedure and practical support.

Admera Health
Booth 519
908.222.0533
ClientCare@admerahealth.com
www.admerahealth.com

Admera Health's CLIA-certified, CAP-accredited diagnostic testing laboratory utilizes Next-Generation Sequencing technology to advance personalized medicine. Our expertise includes pharmacogenomics, cardiovascular disease, and oncology. Physicians and patients receive test results to make more informed treatment decisions.

Advanced Tele-Genetic Counseling (AT-GC)
Booth 1133
888.252.2842
genetics@at-gc.com
www.at-gc.com

AT-GC provides comprehensive genetic consultations and unparalleled expertise in genetic testing implementation and interpretation via telemedicine. Our team consists of certified genetic counselors and medical providers with experience spanning the collective genetic sub-specialties.

AliveAndKickn
Booth 1214
201.694.8282
robin@aliveandkickn.org
www.aliveandkickn.org

AliveAndKickn is a patient advocacy organization whose mission is to improve the lives of individuals and families affected by Lynch Syndrome through research, education, and screening. Ask us about The HEROIC Registry.

Allele Diagnostics
Booth 431
844.255.3532
info@allelediagnostics.com
www.allelediagnostics.com

Allele Diagnostics provides high-quality genetic testing and reporting services. Specializing in rapid microarray, we offer a unique test menu focused on neonatal/pediatric and prenatal patients.

Alnylam Pharmaceuticals
Booth 1033
617.551.8200
info@alnylam.com
www.alnylam.com

Alnylam is leading the translation of RNA interference (RNAi) into a new class of medicines for the treatment of rare genetic, cardio-metabolic, hepatic infectious, and central nervous system diseases. ONPATTRO™ (patisiran) is Alnylam's first U.S. FDA-approved RNAi therapeutic.

Alpha-1 Foundation
Booth 534
877.228.7321
info@alphaone.org
www.alpha1.org

The Alpha-1 Foundation is committed to finding a cure for Alpha-1 Antitrypsin Deficiency and to improving the lives of people affected by Alpha-1 worldwide.

Ambry Genetics
Booth 829
949.900.5500
info@ambrygen.com
www.ambrygen.com

Ambry Genetics is both College of American Pathologists (CAP)-accredited and Clinical Laboratory Improvement Amendments (CLIA)-certified. Ambry is an established leader in clinical genetic diagnostics and genetics software solutions, combining both to offer the industry's most comprehensive genetic testing. Ambry has established a reputation for sharing data while safeguarding patient privacy, unparalleled service, and responsibly applying new technologies to the clinical molecular diagnostics market.

American Board of Genetic Counseling

Booth 1134

913.222.8661

info@abgc.net

www.abgc.net

The American Board of Genetic Counseling (ABGC) is the credentialing organization for the genetic counseling profession in the US and Canada. ABGC works to protect the public and promotes the growth and development of the profession.

American Society of Human Genetics

Booth 1232

301.634.7300

society@ashg.org

www.ashg.org

The American Society of Human Genetics is the primary professional organization for human genetics specialists worldwide. Our mission is to advance human genetics in science, health, and society through excellence in research, education, and advocacy.

Amicus Therapeutics

Booth 1016

609.662.2000

www.amicusrx.com

Amicus Therapeutics is a global biotechnology company at the forefront of therapies for rare and orphan diseases. The Company has a robust pipeline of advanced therapies for a broad range of human genetic diseases.

ARUP Laboratories

Booth 615

801.583.2787

clientservices@aruplab.com

www.aruplab.com

ARUP Laboratories provides high-quality, innovative testing in molecular genetics, cytogenetics, FISH, maternal serum screening, genomic microarray, and biochemical genetics. Our dedicated medical directors and genetic counselors ensure optimal patient care through consultation and interpretation.

AstraZeneca

Booth 610

301.398.0000

www.astrazeneca-us.com

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism and Respiratory.

AveXis

Booth 536

844.428.3947

Info@avexis.com

www.avexis.com

AveXis is a clinical-stage gene therapy company relentlessly focused on bringing gene therapy out of the lab and into the clinical setting for patients and families devastated by rare and orphan neurological genetic diseases.

AXYS

Booth 435

888.999.9428

info@genetic.org

www.genetic.org

Dedicated to providing information, connection and support to individuals with one or more extra X or Y chromosomes including XXY, XYY, XXX and XXYY.

Basser Center for BRCA

Booth 1109

215.662.2748

basserinfo@uphs.upenn.edu

www.basser.org

The Basser Center for BRCA at Penn Medicine's Abramson Cancer Center is the first comprehensive center for the research, treatment, and prevention of BRCA-related cancers. Devoted to advancing care for people affected by BRCA gene mutations, the Basser Center's unique model provides funding for collaborative research, education, and outreach programs around the world.

Batten Disease Support and Research Association (BDSRA)

Booth 1227

800.448.4570

info@bdsra.org

www.bdsra.org

BDSRA is dedicated to funding research for treatments and cures, providing family support services, raising awareness, and advocating for legislative action. BDSRA is the largest support and research organization dedicated to Batten disease in North America.

Exhibitor Index (continued)

Baylor Genetics
Booth 525
800.411.4363
help@baylorgenetics.com

A pioneer of precision medicine for nearly 40 years, Baylor Genetics now offers a full spectrum of clinically relevant genetic testing, access to world-renowned experts, and the confidence to provide patients with the best care.

Biogen
Booth 1132
www.biogen.com

At Biogen, our mission is clear: we are pioneers in neuroscience. Since our founding, Biogen has led innovative scientific research with the goal to defeat devastating neurological diseases.

BioMarin Pharmaceutical Inc.
Booth 718
415.506.6700
www.biomarin.com

BioMarin develops innovative biopharmaceuticals. Approved products include therapies for PKU, LEMS, MPS I, MPS VI, MPS IVA, and CLN2 disease. Development programs include investigational therapies for Hemophilia A, Achondroplasia, MPS IIIB, Friedreich's Ataxia.

Blueprint Genetics
Booth 732
650.452.9340
www.blueprintgenetics.com

Blueprint Genetics delivers quality genetics testing to the global clinical community. We provide clinicians, and their patients, with comprehensive and high-quality tools and resources for diagnostics of genetic conditions.

Boulder Abortion Clinic, PC.
Booth 708
303.447.1361
www.drhern.com

Boulder Abortion Clinic's Dr. Warren Hern provides services to select patients beyond 30 menstrual weeks for fetal anomaly and maternal indications. Assistance with genetic testing and grievance services is available.

CancerIQ, Inc
Booth 1136
312.579.0644
info@cancer-iq.com
www.canceriq.com

CancerIQ is an end-to-end software solution that automates the full administrative workflow for genetics providers including family history collection, pedigree drawing, test ordering, and documentation.

Capital Women's Services
Booth 936
202.945.4940
molly@capitalwomensservices.com
www.capitalwomensservices.com

Capital Women's Services is deeply committed to reproductive freedom for all women. We strive to provide abortion care in a kind, caring, compassionate and respectful manner. We are pro-woman, pro-family, pro-child, and pro-choice.

CBR a California Cryobank Company
Booth 1229
888.932.6568
www.cordblood.com

CBR is the world's leader in newborn stem cell cryo-preservation. The company is dedicated to advancing newborn stem cell research, quality processing and storage, and helping families in need through the Newborn Possibilities Program.

Celmatix
Booth 510
646.835.2864
k.risbrudt@celmatix.com
www.celmatix.com

Celmatix is a next-generation women's health company transforming the way women and their physicians leverage genomics and data to make more informed, proactive reproductive health decisions.

Center for Fetal Diagnosis and Treatment at The Children's Hospital of Philadelphia

Booth 934

800.IN UTERO (468.8376)

www.fetalsurgery.chop.edu

Over twenty years of dedication to advances, excellence and hope, the world's largest prenatal therapy program has welcomed more than 23,000 families from around the world. Team members pioneered the surgical techniques and protocols that today define the field. A leader of the landmark Management of Myelomeningocele Study proving the efficacy of fetal surgery for MMC. Celebrating a decade of births in the world's first delivery unit housed within a pediatric hospital, dedicated exclusively to pregnancies complicated by birth defects.

Centogene US, LLC

Booth 632

617.580.2102

customer.support-us@centogene.com

www.centogene.com

CENTOGENE – Worldwide leader in the field of genetic diagnostics for rare hereditary diseases. Our mutation database (CentoMD®) is the world's largest for and is pivotal to our high-quality diagnostic reporting and comprehensive medical interpretation.

ClinGen

Booth 513

clingen@clinicalgenome.org

www.clinicalgenome.org

The Clinical Genome Resource (ClinGen) is an NIH-funded effort to identify clinically relevant genes and variants for use in precision medicine and research.

Color

Booth 1129

844.352.6567

pam@color.com

www.color.com

Color is a health service that helps you understand your genetic risk for common hereditary cancers and hereditary high cholesterol, and use this knowledge to create a personalized healthcare plan.

Concert Genetics

Booth 1026

615.861.2634

info@concertgenetics.com

www.concertgenetics.com

Concert Genetics is a software and data analytics company that builds products to simplify the comparison, selection, ordering, resulting, billing and payment of genetic tests.

Connective Tissue Gene Tests

Booth 917

484.244 2900

inquiries@ctgt.net

www.ctgt.net

CTGT offers over 1,500 molecular genetic tests and panels for inherited genetic disorders with high test sensitivity and accuracy, fast TAT, expert interpretation and superior customer service. All tests can be performed on prenatal specimens.

CooperGenomics

Booth 933

info@coopergenomics.com

CooperGenomics is the pioneer and global leader of reproductive genetic testing, including preimplantation genetic screening and diagnosis (PGS and PGD). We are on a mission to advance the field of reproductive medicine, improve outcomes, and empower families worldwide.

Counsyl a Myriad Genetics Company

Booth 1015

800.469.7423

cscomments@myriad.com

www.counsyl.com

Counsyl provides women and their families with actionable information to guide critical and timely health decisions. We seek to transform the execution and delivery of complex genetic testing through our high-value screens and comprehensive suite of end-to-end workflow solutions for healthcare providers.

Covenant Health

Booth 1115

865.374.5382

mdugger@covhlth.com

www.covenantcareers.com

Covenant Health is east Tennessee's top-performing healthcare network with nine acute-care hospitals, outpatient and specialty services, and Covenant Medical Group, our area's fastest-growing physician practice division.

DNA Genotek

Booth 512

613.723.5757

alison.slack@dnagenotek.com

www.dnagenotek.com

DNA Genotek Inc. provides non-invasive, patient-friendly DNA and RNA collection kits. Oragene®, an all-in-one kit to collect, stabilize and transport DNA from saliva, enables easy collection, transport and storage while ensuring highest quality genetic results.

Exhibitor Index (continued)

EGL Genetics
Booth 834
470.378.2200
eglmarketing@egl-eurofins.com
www.egl-eurofins.com

With over 50 years of experience, EGL Genetics is an established leader in genetic diagnostic testing. EGL is one of the few labs in the country to offer molecular genetics, biochemical, and cytogenetics tests under one roof.

FamHis, Inc.
Booth 637
866.484.7890
info@famhis.net
www.famhis.net

FamHis is the developer of MyFamilyEMR.com, the premier platform for patients to record their family histories and share with clinicians. A patient (free) and clinician portal allow for communication between both parties. Mobile App included.

FORCE: Facing Our Risk of Cancer Empower
Booth 1135
866.288.7475
info@FACINGOURRISK.ORG
www.facingourrisk.org

FORCE (Facing Our Risk of Cancer Empowered) is the voice of the hereditary breast, ovarian and related cancers community, providing support, education, advocacy, awareness and research to all those traveling their hereditary cancer journey.

Fulgent Genetics
Booth 524
626.350.0537
Info@FulgentGenetics.com
www.FulgentGenetics.com

Fulgent Genetics is committed to surpassing the status quo, we believe in expanding diagnostic solutions. By merging the fields of genetics, molecular biology, and computer science, we pursue excellence in genetic sequencing, scalability, and data analysis. Offering unrivaled flexibility in diagnostic testing, affordable genomic sequencing, and provider services, Fulgent is here to make a difference in patient care.

Geisinger
Booth 427
570.701.7339
gblowry@geisinger.edu
www.geisinger.org

Geisinger is a physician-led health system comprised of approximately 30,000 employees, including 1,600 physicians, 13 hospital campuses, two research centers, medical school, and a 583,000-member health plan. Geisinger is nationally recognized for innovative practices and quality care.

Gene42, Inc.
Booth 1230
888.682.5252
info@gene42.com
www.gene42.com

Gene42 develops software for the investigation and treatment of people with genetic-based disease. The team of computer scientists, software engineers, and medical experts develops PhenoTips software to solve today's challenges and discover tomorrow's opportunities in medical genetics.

GeneDx Inc.
Booth 809
301.519.2100
GeneDx@GeneDx.com
www.genedx.com

GeneDx, Inc. is a global leader and pioneer in advanced genetics and genomics testing, providing specialized services to patients and their families in over 55 countries for nearly 20 years.

GeneMatters
Booth 709
866.741.5331
info@gene-matters.com
www.Gene-Matters.com

GeneMatters offers telehealth genetic counseling for timely access to genetic counselors for your patients. We partner to provide genetic expertise, immediate access, easy and flexible integration through our customized platform, cost-effectiveness and independence.

Genetic Support Foundation
Booth 508
844.743.6384
info@geneticsupport.org
www.geneticsupportfoundation.org

Genetic Support Foundation is an independent organization that provides genetic counseling services and educational resources. For genetic counselors, it provides a supportive, collaborative environment.

Geneveda
Booth 607
877.269.0090
www.geneveda.com

Geneveda offers a comprehensive portfolio of high complexity, state-of-the-art, automated molecular analysis, including NGS technology, to empower clinicians to better understand their patient's risk for hereditary disorders to individualize and improve patient care.

Genome Medical
Booth 1119
877.688.0992
info@genomemedical.com
www.genomemedical.com

Genome Medical is a national telegenomics technology and services company that is bringing genetics to everyday health care. Our clinical team provides expert genetic care for individuals and their families to improve health and well-being.

GenPath Women's Health
Booth 808

GenPath Women's Health, a division of BioReference Laboratories, Inc., specializes in the diagnostic needs of MFMs/Ob-Gyns for preconception/prenatal testing, and offers hereditary cancers testing through GeneDx, Inc. BioReference and GeneDx are OPKO Health companies.

Greenwood Genetic Center
Booth 616
888.GGC.GENE
www.ggc.org

The Greenwood Genetic Center is a nonprofit institute organized to provide clinical genetic services, diagnostic laboratory testing, educational programs and resources and research in the field of medical genetics. Our laboratory offers biochemical, cytogenetic, and molecular testing.

Igenomix
Booth 1228
305.501.4948
infousa@igenomix.com
www.igenomix.us

Igenomix is a reproductive genetics company whose experience and advanced research capabilities have placed them among the world leaders in the field, enabling them to provide effective solutions tailored to different infertility problems, with lab operations in Miami, Los Angeles, New York, and 11 other laboratory affiliates around the world.

Illumina, Inc.
Booth 515
858.202.4500
info@illumina.com
www.illumina.com

A global genomics leader, Illumina provides comprehensive next-generation sequencing solutions to the research, clinical, and applied markets. Illumina technology is responsible for generating more than 90% of the world's sequencing data.

InformedDNA
Booth 535
800.975.4819
info@informeddna.com
www.informeddna.com

InformedDNA is the authority on the appropriate use of genetic testing. We leverage the expertise of the largest staff of board-certified genetics specialists to counsel and advise health plans, hospitals, providers and patients.

Integrated Genetics
Booth 617
800.848.4436
www.integratedgenetics.com

Integrated Genetics is a leading provider of reproductive genetic testing services driven by its commitment to physicians and their patients. With the addition of Sequenom, a pioneer in the fast-growing area of non-invasive prenatal testing, Integrated Genetics can now offer physicians and patients more options for prenatal testing.

Invitae
Booth 703, 706
800.436.3037
clientservices@invitae.com
www.invitae.com

Invitae's mission is to bring comprehensive genetic information into mainstream medical practice to improve the quality of healthcare for billions of people. Our goal is to aggregate most of the world's genetic tests into a single service with higher quality, faster turnaround time and lower prices.

Exhibitor Index (continued)

Johns Hopkins Center for Fetal Therapy
Booth 526
410.502.6561
fetaltherapy@jhmi.edu

The Johns Hopkins Center for Fetal Therapy provides state-of-the art treatment for complex fetal conditions including twin-twin-transfusion syndrome, spina bifida, congenital diaphragmatic hernia, urinary tract obstruction and fetal tumors. Our multidisciplinary care approach integrates expertise in open and closed fetal interventions, fetoscopic surgery, maternal, neonatology, pediatric, genetic and social services located at one of the leading medical institutions in the nation. Our fetal therapy physician hotline – 1-844-JH-FETAL – provides 24/7 access to care.

Johns Hopkins Genomics
Booth 428
410.614.1075
ddl@jhmi.edu
www.jhgenomics.jhmi.edu

Integrating expertise, enabling data discovery, informing patient care.

JScreen at Emory University
Booth 412
404.778.8640
info@jscreen.org
www.jscreen.org

JScreen provides at-home, saliva-based carrier screening, in conjunction with patient education and genetic counseling services.

Kaiser Permanente – Northern Calinfornia
Booth 711
408.972.3306
Jazmine.Jung@kp.org
www.genetics.kp.org

Practice what you believe, practice at Kaiser Permanente! Kaiser Genetics is the employer of choice for over 70 genetic counselors in Northern California.

Laboratory for Molecular Medicine- Partners Personalized Medicine
Booth 517
617.768.8500
lmm@partners.org
www.personalizedmedicine.partners.org/Laboratory-For-Molecular-Medicine/Default.aspx

The Laboratory for Molecular Medicine (LMM) is a CLIA-certified molecular diagnostic laboratory, operated by Partners HealthCare Personalized Medicine and is led by a group of Harvard Medical School-affiliated faculty, geneticists, clinicians, and researchers.

Le Bonheur Children's Hospital
Booth 437
901.287.5080
patricia.tripp@mlh.org
www.lebonheur.org

Le Bonheur is a free standing pediatric acute care facility located in Memphis, TN. Recognized among the nation's "Best Children's Hospital" by *US News & World Report* for seven consecutive years.

Lettercase: National Center for Prenatal and Postnatal Resources
Booth 408
770.310.3885
info@lettercase.org
www.lettercase.org

The Lettercase National Center for Prenatal and Postnatal Resources offers patient-friendly, accurate, balanced, and up-to-date resources about multiple genetic conditions, which are reviewed by representatives of the national medical and advocacy organizations.

MNG Laboratories
Booth 504
678.225.0222
quickresponse@mnglabs.com
www.mnglabs.com

MNG Laboratories is a leading provider of neurogenetic testing through clinical services, complex biochemical testing and sequencing. With over 15 years of diagnostic experience, MNG strives to deliver added value to our client's needs.

Myriad Genetic Laboratories, Inc.
Booth 1025
801.584.3600
cscomments@myriad.com
www.myriad.com

Myriad Genetics Inc., is a leading personalized medicine company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics.

National Coordinating Center for the Regional Genetics Networks (NCC)
Booth 424
301.718.9603
ncc@nccrcg.org
www.nccrcg.org

The seven Regional Genetics Networks (RGNs), their National Coordinating Center (NCC), and the National Genetics Education and Family Support Center (Family Center) mission is to increase access to quality genetic services for medically underserved communities.

National Down Syndrome Congress

Booth 1233

770.604.9500

ndsc@ndsccenter.org

www.ndsccenter.org

The NDSC promotes the interests of people with Down syndrome and their families through advocacy, public awareness, and information. We reshape the way people understand and experience Down syndrome. We educate, advocate, empower and inspire.

NCATS/Genetic and Rare Diseases Information Center

Booth 1212

888.205.2311

GARDinfo@nih.gov

www.rarediseases.info.nih.gov

GARD is a program of the National Center for Advancing Translational Sciences (NCATS) that provides current, reliable, and easy-to-understand information about rare or genetic diseases in English or Spanish.

NIH Genetic Testing Registry/MedGen/ClinVar

Booth 700

brandi.kattman@nih.gov

www.ncbi.nlm.nih.gov/guide/genetics-medicine

10,300 conditions, 16,445 genes, 443,000 variants and 55,300 genetic tests in 100 square feet. See what's new with NCBI's Medical Genetics and Human Variation resources: ClinVar, GTR, MedGen, dbSNP, dbGaP and more.

Northside Hospital Cancer Institute Cancer Genetics Program

Booth 601

404.851.6284

genetics@northside.com

www.northside.com

Northside Hospital Cancer Institute is a member of the NCI Community Oncology Research Program and one of the largest community cancer programs in the country. Our Cancer Genetics Program employs six genetic counselors, and growing.

Norton & Elaine Sarnoff Center for Jewish Genetics

Booth 1125

312.357.4718

jewishgeneticscenter@juf.org

www.jewishgenetics.org

The Norton & Elaine Sarnoff Center for Jewish Genetics provides community education and other resources related to recessive conditions and hereditary cancers more common in persons of Jewish descent. The Sarnoff Center provides a subsidized carrier screening program in Illinois.

Norton Healthcare

Booth 1210

www.nortonhealthcare.com

For more than a century, the residents of Kentucky and Southern Indiana have trusted the Norton Healthcare name for dedicated and compassionate care. With a network of five hospitals in Louisville, Norton Healthcare is a leader in serving adult and pediatric patients.

Now I Lay Me Down to Sleep (NILMDTS)

Booth 433

720.283.3339

headquarters@nilmdts.org

www.nowilaymedowntosleep.org

NILMDTS offers the gift of healing, hope and honor to parents experiencing the death of a baby through the overwhelming power of remembrance portraits.

NTD Eurofins

Booth 713

631.741.4956

www.ntd-eurofins.com

For more than 30 years, NTD has pioneered the research and development of prenatal screening protocols for open neural tube defects, Down syndrome, trisomy 13 and 18, and early onset preeclampsia screening. Today, NTD serves genetic counselors, obstetricians and maternal fetal medicine specialists worldwide.

Exhibitor Index (continued)

Organization of Teratology Information Specialists/MothertoBaby
Booth 1234
615.649.3082
contactus@mothertobaby.org
www.mothertobaby.org

The Organization of Teratology Information Specialists (OTIS) is a professional scientific society that provides the MotherToBaby services and conducts observational research studies. Members are engaged in assessing and evaluating risks to pregnancy and breastfeeding from exposures, like medications and more. MotherToBaby is a suggested resource by many federal agencies including the Centers for Disease Control and Prevention (CDC).

Parent Project Muscular Dystrophy/ Decode Duchenne
Booth 410
917.273.5020
JEN@parentprojectmd.org
www.endduchenne.org/decode

Parent Project Muscular Dystrophy fights every single battle necessary to end Duchenne. Decode Duchenne provides free genetic testing and counseling to people with Duchenne or Becker muscular dystrophy who have been unable to access genetic testing.

PerkinElmer Genomics
Booth 417
866.354.2910
www.perkinelmergenomics.com

Pairing our decades of experience in newborn screening with a state-of-the-art clinical genomics program, PerkinElmer Genomics provides one of the world's most comprehensive programs for detecting clinically significant genomic changes. Our high-quality, fast, affordable results allow clinicians to offer patients the answers they need to determine their path forward.

Pfizer Oncology
Booth 1113
212.733.2323
www.pfizer.com

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products. Our global portfolio includes medicines and vaccines as well as many of the world's best-known consumer health care products.

Phosphorus Diagnostics
Booth 411
855.746.7423
support@phosphorus.com

Phosphorus is a computational genomics company with the vision to create a world where every healthcare decision is optimized with genomics. Phosphorus offers clinical genetic tests in a range of clinical areas from its CLIA-certified laboratory. We also develop powerful software that enables labs around the world to deliver the most advanced genetic tests.

PreventionGenetics
Booth 907
715.387.0484
clinicaldnatesting@preventiongenetics.com
www.preventiongenetics.com

PreventionGenetics is a CLIA and ISO 15189:2012 accredited clinical DNA testing laboratory. PreventionGenetics provides patients with sequencing and deletion/duplication tests for nearly all clinically relevant genes, including whole exome sequencing, PGxome.

Progenity
Booth 509
855.293.2639
events@progenity.com
www.progenity.com

At Progenity, we partner with clinicians to offer advanced diagnostic tests that help patients and their families Prepare for Life. Progenity's genetic counselors work as part of the healthcare team. Visit us at booth #509 or at progenity.com.

Progeny Genetics
Booth 937
800.776.4369
info@progenygenetics.com
www.progenygenetics.com

Progeny Clinical simplifies the process of managing family history with patient-entered family history questionnaires and integrated cancer risk models built to save you time.

Quest Diagnostics
Booth 729
973.520.2700
www.questdiagnostics.com

Quest Diagnostics empowers people to take action to improve health outcomes. Derived from the world's largest database of clinical lab results, our diagnostic insights reveal new avenues to identify and treat disease, inspire healthy behaviors and improve health care management.

RARE Science, Inc. – RARE Bear Sponsor

Booth 432

In partnership with RARE Science, Inc., join NSGC's special RARE Bear Stuff-and-Sew event in booth #432 any time the exhibit hall is open to help us reach our goal of completing 100 RARE Bears during this year's conference. The RARE Bear program, that gifts one-of-a-kind bears to one-of-a-kind kids, brings instant joy and globally unites rare communities seeding biological understanding of rare diseases of children on the way to improved therapies.

Rare Genomes Project (Broad Institute)

Booth 430

617.714.7395

raregenomes@broadinstitute.org

www.raregenomes.org

The Rare Genomes Project uses genome sequencing to molecularly diagnose patients with rare, suspected genetic conditions through a nationwide partnership with families and their clinicians. Participation is remote, and clinically-relevant findings are CLIA confirmed.

Recordati Rare Diseases Inc.

Booth 812

908.236.0888

info@recordatirarediseases.com

www.recordatirarediseases.com

Recordati Rare Diseases is committed to providing often overlooked orphan therapies to the underserved rare disease communities. Our team works side-by-side with rare disease communities to increase awareness, improve diagnosis, and expand availability of treatments.

Retrophin, Inc

Booth 1111

760.260.8600

www.retrophin.com

Retrophin is a biopharmaceutical company dedicated to delivering life-changing therapies to people living with rare diseases who have few, if any, treatment options.

Roche Diagnostics

Booth 1006

www.harmonytestusa.com

Roche provides innovative diagnostic solutions to help clinicians make confident decisions for their patients' health, including the Harmony non-invasive prenatal test, a lab-developed (non-FDA approved) test to evaluate risk of Trisomy 21, 18, and 13.

RPRD Diagnostics

Booth 533

414.316.3097

info@rprdx.com

www.rprdx.com

RPRD Diagnostics specializes in providing innovative and end-to-end pharmacogenomics solutions, including diagnostic, analytical and consulting services to clinicians, researchers and drug developers. Based on decades of experience in pharmacogenomics research, clinical practice, and healthcare program development, RPRD team of experts strives to help clients improve lives of patients using precision medicine.

Sanford Research – CoRDS Registry

Booth 737

877.658.9192

cords@sanfordhealth.org

www.sanfordresearch.org/SpecialPrograms/cords

Based at Sanford Research, a not-for-profit research institution, CoRDS is a centralized international patient registry for all rare diseases. We support patient advocacy groups, individuals, and researchers to coordinate the advancement of research into the 7,000 rare diseases.

Sanofi Genzyme

Booth 600

617.252.7500

www.sanofigenzyme.com

Sanofi Genzyme focuses on developing specialty treatments for debilitating diseases that are often difficult to diagnose and treat, providing hope to patients and their families.

Sarepta Therapeutics

Booth 1105

617.274.4000

info@sarepta.com

www.sarepta.com

Sarepta Therapeutics is a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicines to treat rare neuromuscular diseases. The Company is primarily focused on rapidly advancing the development of its potentially disease-modifying Duchenne muscular dystrophy (DMD) drug candidates and is proud to support the 37th NSGC Annual Conference.

Exhibitor Index (continued)

Seattle Children's Hospital – PLUGS
Booth 625
206.987.3361
PLUGS@seattlechildrens.org
www.seattlechildrenslab.org/plugs

Patient-centered Laboratory Utilization Guidance Services (PLUGS) is a non-profit laboratory stewardship collaboration within Seattle Children's Hospital Department of Laboratories. Our mission is to improve laboratory test ordering, retrieval, interpretation and reimbursement.

Sema4
Booth 1108
475.333.3800
www.sema4.com

Sema4 is a patient-centered predictive health company founded on the idea that more information, deeper analysis, and increased engagement will improve the diagnosis, treatment, and prevention of disease. We build predictive models of complex disease and offer advanced genome-based diagnostics for reproductive health and oncology.

Sharsheret
Booth 1127
201.833.2341
pcottrell@sharsheret.org
www.sharsheret.org

Sharsheret supports young Jewish women and families facing breast and ovarian cancer – before, during, and after diagnosis – including those at high genetic risk. We provide educational resources, offer individualized support, and create local awareness programs.

Shire
Booth 532
216.470.0547
ddavies@shire.com
www.shire.com

Shire is the leading global biotechnology company focused on serving people with rare diseases and those with specialty needs.

Simons VIP Connect
Booth 530
855.329.5638
coordinator@simonsvipconnect.org
www.simonsvipconnect.org

Simons VIP Connect is on an online community, resource center, and portal to research opportunities for families with genetic diagnoses associated with features of autism and developmental delay.

Southwestern Women's Options
Booth 1117
505.242.7512
swoadmin@covad.net
www.southwesternwomens.com

Southwestern Women's Options offers pregnancy terminations with no gestational limit for patients whose pregnancies have been diagnosed with fetal abnormalities. Our services are designed to meet your patient's needs in an atmosphere of warmth and respect.

Special Angels Adoption
Booth 1107
740.395.3097
Jennifer@specialangelsadoption.org
www.specialangelsadoption.org

Special Angels Adoption handles exclusively special needs adoptions all over the United States. Working with birth and adoptive families in all states allows us to serve our mission of helping all families of children with special needs.

St. Jude Children's Research Hospital
Booth 1216
901.595.2339
www.stjude.org

St. Jude Children's Research Hospital, located in Memphis, Tennessee, is one of the world's premier pediatric cancer research centers. Its mission is to find cures for children with cancer and other catastrophic diseases through research and treatment.

Stealth BioTherapeutics
Booth 405
617.600.6888
www.stealthbt.com

Stealth is an innovative biopharmaceutical company developing therapies to treat the mitochondrial dysfunction associated with genetic mitochondrial diseases and many common age-related diseases. Stealth's mission is to lead the development of mitochondrial medicine to improve the lives of patients with diseases involving mitochondrial dysfunction, an area of high unmet clinical need.

Texas Children's Pavilion for Women – Fetal Center
Booth 736
832.822.2229
emmore@texaschildrens.org
www.women.texaschildrens.org/program/texas-childrens-fetal-center

Texas Children's Fetal Center®, located in Houston, TX, is one of the nation's leaders in the diagnosis and treatment of abnormalities in unborn and newborn infants.

The Children's Hospital of Philadelphia

Booth 426

215.590.0637

robertsj1@email.chop.edu

www.chop.edu/labs

The Division of Genomic Diagnostics at CHOP provides a wide spectrum of testing for genetic conditions, cancer diagnosis and treatment, histocompatibility and immunogenetics, and pharmacogenomics.

The Focus Foundation

Booth 735

443.223.7323

dexy@thefocusfoundation.org

www.thefocusfoundation.org

The Focus Foundation is a nonprofit research organization specializing in the research and treatment of children with X and Y chromosomal variations, such as 47,XXY, 47,XYY, 48,XXXX, 48,XXXY, 48,XXYY, and 49,XXXXY; dyslexia; and developmental dyspraxia.

The Marfan Foundation

Booth 1235

516.883.8712

staff@marfan.org

www.marfan.org

Through research, patient support, and education, The Marfan Foundation creates a brighter future for everyone affected by Marfan syndrome and related conditions.

ThinkGenetic

Booth 1014

866.417.7348

contact@thinkgenetic.com

www.thinkgenetic.com

ThinkGenetic, Inc. aims to reduce the time to a genetic diagnosis with accessible content, tools and data services that spark meaningful action. We empower people alongside their journey of living with genetic conditions.

TrakGene

Booth 425

+61.407.18099

kvandiemen@trakgene.com

www.trakgene.com

TrakGene delivers a Genetics Information Management Solution to effectively and efficiently manage all aspects of a Genetics Service. TrakGene's specialised genetics electronic health record combines pedigrees, demographic data, genetic information, risk tools and sophisticated reporting.

UAB Medical Genomics Laboratory

Booth 614

205.934.5562

medgenomics@uabmc.edu

www.genetics.uab.edu/medgenomics

The UAB Medical Genomics Laboratory (MGL) is a CAP-certified, non-profit clinical laboratory, offering comprehensive testing for both common and rare genetic disorders, while specializing in the neurofibromatoses, rasopathies, and tuberous sclerosis.

UCLA Health

Booth 1018

310.267.3292

www.uclahealthcareers.org

UCLA Health defines greatness by the quality of the patient experience we are able to deliver. Each and every time. To every single patient. If that's where your ambitions lie, UCLA is where you belong.

UCSF Fetal Treatment Center

Booth 627

800.793.3887

fetus@ucsf.edu

www.fetus.ucsf.edu

The UCSF Fetal Treatment Center is a world leader in diagnosing and treating birth defects before delivery. We offer comprehensive, family-centered care in one location, from diagnosis and prenatal management through postnatal care and long-term follow-up.

Undiagnosed Diseases Network (UDN)

Booth 407

844.746.4836

UDN@hms.harvard.edu

www.udnconnect.org

The UDN is a research study funded by the NIH Common Fund. Its purpose is to bring together clinical and research experts from across the United States to solve medical mysteries using advanced technologies.

University of Chicago Genetic Services Laboratories

Booth 716

773.834.0555

ucgslabs@genetics.uchicago.edu

www.dnatesting.uchicago.edu

University of Chicago Genetic Services Laboratories is a CLIA- and CAP-certified laboratory offering cutting-edge DNA diagnostic services. We offer a wide range of tests for rare diseases including exome sequencing and panel based testing.

Exhibitor Index (continued)

University of Washington
Booth 1024
800.713.5198
commserv@uw.edu
www.depts.washington.edu/labweb

UW-OncoPlex is a multiplexed gene sequencing panel that detects mutations in tumor tissue in 194 cancer-related genes; BROCA genetic risk panel for 62 genes; Coloseq and Coloseq Tumor genetic test using NGS.

UNMC Human Genetics Laboratory
Booth 925
402.559.5070
humangenetics@unmc.edu
www.unmc.edu/geneticslab

The Human Genetics Laboratory at the University of Nebraska Medical Center (UNMC) is a full-service clinical cytogenetics and molecular genetics laboratory specializing in both constitutional (prenatal and postnatal) and cancer diagnostics for over 40 years.

UPMC
Booth 1231
412.667.7261
davisa19@upmc.edu
www.upmc.com

A world-renowned health care provider and insurer, Pittsburgh-based UPMC is inventing new models of accountable, cost-effective, patient-centered care. UPMC's unique strategy of combining clinical and research excellence with business-like discipline translates into high-quality patient care.

Valley Children's Healthcare
Booth 429
559.353.7058
dyee@valleychildrens.org
www.valleychildrens.org

Join Valley Children's Healthcare, one of the nation's ten largest pediatric hospitals located in affordable Central California. Excellent full-time Genetic Counselor opportunity in our Metabolic Genetics and Maternal Fetal Center. Come visit our booth!

Variantyx Inc
Booth 835
617.209.2090
info@variantyx.com
www.variantyx.com

Variantyx provides Variantyx Unity™ a whole genome sequencing (WGS) based test for diagnosis of rare inherited disorders. We also enable hospitals and labs to profitably expand their test menu with validated genomic diagnostic solutions.

Women's Care Florida
Booth 528
813.286.0033
rcuti@womenscarefl.com
www.womenscarefl.com

Women's Care Florida specializes in obstetrics and gynecology, gynecologic oncology, urogynecology, gynecologic pathology and breast surgery, with a growing genetic counseling specialty. WCF has 73 offices and 230+ providers throughout Tampa Bay and Central Florida.

IF YOUR PATIENT HAS ANY OR ALL OF THESE SYMPTOMS...

- EPISODIC APNEA
- SWALLOWING DIFFICULTIES
- SERONEGATIVE MYASTHENIA
- RESPIRATORY CRISIS
- DROOPY EYELIDS
- UNUSUAL FATIGUE
- EARLY OR LATE ONSET

...it is possible they have one of the potentially severe

CONGENITAL MYASTHENIC SYNDROMES (CMS)

- Clinical trial enrollment is currently underway for some sub-types and involves amifampridine phosphate treatment
- Genetic testing will be provided to suspected CMS cases
- Travel and lodging provisions provided through NORD

Learn more at **catalystpharma.com**
E-mail us at **info@catalystpharma.com**
Call toll-free: **1-844-347-3277**

Catalyst pharmaceuticals

Catalyst Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating diseases. We are honored to not only work for patients with rare diseases but to work with them towards hope for a brighter future.

Save the Date!

National Society of Genetic Counselors
Celebrating 40 Years
1979 – 2019



38th Annual Conference

November 5-8, 2019

Salt Lake City, Utah
Salt Palace Convention Center